

1 **ABSTRACT**

2 **Background:** With increasing demands on the National Health Service (NHS), Scottish Government-
3 led pharmacy strategy has prioritised the development and expansion of outpatient services. Pharmacist-
4 led outpatient clinics have been shown to reduce hospital admissions and improve patient outcomes.
5 However, expanding these contemporary models of care has proved challenging, and there are few
6 qualitative data about the factors affecting the provision of these.

7 **Aim:** This study aimed to explore the enablers and barriers to hospital pharmacists providing outpatient
8 clinics within the largest health authority in Scotland, NHS Greater Glasgow & Clyde (NHSGGC).

9 **Method:** Between August and October 2020, one-to-one semi-structured interviews were conducted
10 virtually using the videoconferencing platform Microsoft Teams[®], with NHSGGC hospital pharmacists
11 who did or did not provide clinics. Audio- and video-recordings of the interviews were transcribed
12 verbatim and underwent thematic analysis.

13 **Results:** 16 hospital pharmacists were interviewed; 50% were clinic providers and 50% were not.
14 Analysis generated seven themes: clinical or service need, individual factors, clinic structure and
15 processes, additional clinical skills and training, competing priorities, macro-level pharmacy working,
16 and external stakeholder relationships. Many of these were interdependent and had the potential to be
17 an enabler or a barrier to clinic provision, depending on the context or individual.

18 **Conclusion:** The enablers and barriers to hospital pharmacists providing outpatient clinics are
19 multifaceted, incorporating individual, systematic and professional factors. The implementation of new
20 national professional curricula may help address many of these factors, however prospective research
21 needs to accompany this vision.

22

23 **Impact of findings on practice:**

- 24 • The barriers and enablers to the provision of a pharmacist-led outpatient clinic described in this
25 study provide a basis for better understanding the factors contributing to the inertia in hospital
26 pharmacist-led clinic formation and expansion.
- 27 • A broader over-arching question of ‘whose job is it to develop new roles and new services’
28 remains unclear from this study.
- 29 • The implementation of new professional curricula may offer potential solutions by supporting
30 both the development of clinical skills, including autonomously managing clinical risk, and
31 non-clinical skills, inclusion leadership, and service development.
- 32 • Future research should evaluate the impact of such an approach and implementation science
33 frameworks may also offer additional means to realise this change at the macro-level.

34 INTRODUCTION

35 Day-to-day roles of pharmacists worldwide have developed over the last thirty years beyond traditional
36 dispensing roles, to now also include tasks relating to medication review, optimisation, and monitoring
37 [1]; such roles are known to improve patient outcomes and treatment goals [2, 3]. Additionally, in many
38 countries pharmacists have been provided with the legal premise to prescribe medicines; and there is
39 growing evidence that the effectiveness and safety of autonomous non-medical prescribers, including
40 pharmacists, are comparable to those delivered by medical prescribers in a variety of clinical settings
41 [4, 5].

42 United Kingdom (UK) legislation has enabled pharmacists to become independent prescribers upon
43 successful completion of an accredited course; this usually consists of university-based taught
44 components and experiential based learning [6, 7]. Pharmacist Independent Prescribers (PIPs) have
45 demonstrated their benefits for inpatients whilst working in the acute hospital-based setting [8, 9].
46 However through clinic provision, PIPs have also shown their value for outpatients by optimising
47 medicines with known prognostic importance [10, 11]. In Scotland, an increasingly elderly and multi-
48 morbid population pose sustainability challenges to the National Health Service (NHS), requiring a
49 modernisation of the multidisciplinary skill mix and sector of care in which care is delivered [12-17].

50 Scottish Government pharmacy strategy has prioritised utilising the expertise of pharmacists to improve
51 the delivery of services, such as outpatient services and clinics [18]. For hospital pharmacists, a major
52 component of these services is the provision of outpatient duties which encompasses the greater use of
53 PIPs in specialist clinics within both community- and hospital-based settings. [18, 19]. Exemplar
54 models of pharmacist-led clinics utilising advanced skills, such as clinical examination and
55 venepuncture, and independent prescribing (IP) qualification, in specialties like cardiology, have
56 produced measurable benefits [20]. However, anecdotal evidence suggests the expansion of these clinic
57 models into other specialities is limited.

58 There appears to be few worldwide qualitative data about the enablers and barriers to the provision of
59 hospital-based pharmacist-led clinics which is perhaps indicative of how this specialist outpatient role
60 is still in its relative infancy. Despite including pharmacists, findings from a tri-continental study
61 designed to determine the enabler and barriers to hospital-based clinicians establishing post-ICU clinics
62 are limited by their aggregation with that of other healthcare professionals (HCPs), meaning pharmacist-
63 specific enablers and barriers are non-extractable [21]. Other exploratory studies only address the
64 behavioural intentions and expectations of hospital pharmacists potentially expanding their services,
65 with no practical observations and information about service expansions and provision [22, 23].

66 The rationale for this new study was to provide findings that would help inform future local practical
67 implementation strategies for scaling up pharmacists involvement in outpatient clinics, in line with
68 government policy.

69

70 **Aim**

71 This study aimed to explore the enablers and barriers to hospital pharmacists providing outpatient
72 clinics within the largest health authority in NHS Scotland.

73

74 **Ethics approval**

75 The NHS West of Scotland Research Ethics Service Scientific Officer advised that ethical review was
76 not required, on the basis that this study was a service evaluation aiming to deliver government strategy
77 [18]. Approval was obtained, from local governance teams within the health authority, as this study
78 formed part of a wider pharmacy service evaluation.

79

80 **METHOD**

81 **Setting**

82 This study was conducted within NHS Greater Glasgow & Clyde (NHSGGC), the largest autonomous
83 regional health authority in Scotland which provides healthcare to a population of 1.14 million residents
84 [24]. 34% of the most socially and economically deprived areas in Scotland are within the NHSGGC
85 authority [25]. Approximately, 170 pharmacists work across nine hospitals in NHSGGC.

86 **Sampling**

87 Our purposive sampling strategy aimed to recruit pharmacists working within different hospital sites
88 and specialties (e.g. cardiology, oncology, mental health), as well as different levels of hospital and
89 clinic experience [26, 27]. A sample of between 12-20 participants was estimated to potentially achieve
90 data saturation [27-30], whilst we intended to have an equal number of hospital pharmacists who
91 provided, and did not provide, an outpatient clinic. The intended goal of the sample was to provide a
92 breadth of experiences about both the enablers and barriers to outpatient clinic provision.

93 Participant inclusion criteria were permanent or fixed-term employed hospital pharmacists of any level,
94 pay grade, or seniority; who worked in any of the nine hospital sites within NHSGGC [24]. Exclusion
95 criteria included: those on maternity/paternity or sick leave at the time of the study; and the researchers,
96 who were pharmacists, involved in the study. Additionally, pharmacists with less than two years post-
97 registration experience were excluded since they would ha²ve been in an early career training position
98 and would be ineligible to gain the additional qualifications (e.g. IP) and experience that are needed to
99 potentially provide a pharmacist-led outpatient clinic [6, 7].

100 **Participant recruitment**

101 A participant information leaflet was disseminated in an internal email in February 2020 by the lead
102 pharmacist for all hospital pharmacists within NHSGGC; a reminder email was sent two weeks later.
103 All interested participants were invited to contact the lead author by email or telephone, who issued

104 consent forms that were completed and returned by email or post. No incentives were offered for
105 participation.

106 **Data collection and handling**

107 Prior to the interviews, two semi-structured interview schedules (one for those who provided
108 pharmacist-led clinics and one for those who did not) were developed (GB, PF) based on the aims of
109 the study. The schedule were then piloted on one independent pharmacist with four months experience
110 of outpatient service provision, modified and developed for use in the main study (see Supplementary
111 File); these pilot interview data were excluded from the study. Due to the COVID-19 pandemic,
112 interview dates were postponed and took place between August and October 2020. At this point each
113 participant was contacted and invited to participate in an online interview using the videoconferencing
114 platform Microsoft Teams® [31]. At the interview, each participant reaffirmed their consent verbally
115 and were informed that the main purpose of the interview was to explore their own views and
116 experiences on clinic provision, and to describe factors that enabled or prevented them from doing this.
117 All interviews lasted between 15-30 minutes, and were video-recorded; these interviews were
118 subsequently transcribed in verbatim and anonymised (GB). These transcripts were then accuracy
119 checked by an independent staff member who did not take part in the study. All electronic data were
120 stored on encrypted and password protected NHS computers. After transcription and validation, all
121 recordings were deleted.

122 **Data analysis**

123 Both coders (GB and PF) were male pharmacists, with a range of experience from 6 to 19 years working
124 in hospital and community-based pharmacy respectively. All transcripts were uploaded onto the
125 qualitative data analysis software NVivo 12.0 (QSR International Pty Ltd.) [32]. All transcribed data
126 underwent thematic analysis using Braun and Clarke's recommended six phases [33, 34]. After
127 familiarisation with the raw transcript data, and with a primary focus on the study aim, an inductive
128 approach was used to segment the data into meaningful categories and descriptors (i.e. generating initial
129 codes). One quarter (n=4) of all transcriptions were independently coded (GB and PF), with a random

130 number generator used to select transcripts. From this, a preliminary coding scheme was produced, and
131 applied, across all past and future interviews; transcripts were reviewed continuously with constant
132 comparisons made between the generated codes and the data to allow the incorporation of consistent
133 and differing responses (GB). Patterns of this coded data were collated into broader concepts which
134 linked them together (i.e. themes) [33-35]. The derivation, review, and refinement of themes were
135 discussed regularly (GB and PF), and continued until each theme was defined and had a clear narrative
136 that was relevant to the aim of this study. Analysis continued concurrently with further participant
137 recruitment until data saturation was achieved; further participant recruitment stopped at this stage [33,
138 36]. Once all interviews were included, and to provide an external check on the data and analysis
139 process, these themes and sub-themes were critiqued and validated by an experienced qualitative
140 research associate (ED) [34, 37, 38]. Differences in interpretation were resolved by consensus; both
141 semantic and latent themes, with sub-themes, emerged from the data. The reporting of this study
142 conforms to the consolidated criteria for reporting qualitative studies (COREQ) guidelines—(see
143 ~~Supplementary File~~) [39].

144

145 **RESULTS**

146 Data saturation was achieved after 16 hospital pharmacists were interviewed; their characteristics are
147 presented in Table 1. Most participants were female (n=11) and median age was 38 years. Other
148 professional and demographic characteristics were broadly similar between the clinic- and non-clinic-
149 providing pharmacist cohorts. Analysis generated seven themes relating to enablers and barriers; many
150 of these were interdependent and had the potential to be an enabler or a barrier to clinic provision,
151 depending on the context or individual. A narrative of each theme and sub-theme is detailed below and
152 illustrative quotes for each are presented in Table 2.

153 **Clinical or service need**

154 Most pharmacists providing an outpatient clinic described its establishment following an increased
155 service or clinical demand. Examples of clinical demands were: the need for the therapeutic monitoring
156 of medicines, post-discharge medication optimisation or patients requiring consideration for a newly
157 approved medicine.

158 **Individual factors**

159 *Personal motivation*

160 All participants cited a personal motivation to progress their career and achieve greater job satisfaction
161 through clinic provision. However, confidence and a locus of control frequently regulated their ability
162 to achieve this.

163 *Confidence with Risk*

164 Limited experience in the clinic environment was a major obstacle, with most participants disclosing
165 an apprehension about the potential clinical risks associated with the increased responsibility of the
166 outpatient role. Others revealed a perceived “fear of the unknown” associated with some aspects of
167 clinic provision. Examples included: physical patient assessment, being left alone in the clinic room
168 with a patient, or having to unexpectedly manage a very unwell or complicated patient. However, all

169 clinic-providing pharmacists stated that these initial anxieties faded over time as they gained more
170 confidence and experience through the sustained delivery of their clinic.

171 *Locus of Control*

172 Many clinic-providing participants portrayed a strong internal locus of control where they proactively
173 engaged with their multidisciplinary team (MDT), and drove the establishment of their outpatient roles
174 themselves; rather than relying upon their pharmacy department or management team. This strong
175 leadership often fostered creative solutions to barriers and facilitated external funding and resource for
176 their outpatient role.

177 In contrast, an external locus of control predominated in the non-clinic providers who described a need
178 to be directly presented with opportunities and resources from either pharmacy management or the
179 MDT; whilst some divulged previous unsuccessful requests for funding from pharmacy services.
180 Pertinent to this was a perceived requisite to obtain permission from pharmacy management before
181 pursuing potential outpatient roles within their MDTs. However, there were no formal examples of
182 permission being denied, and even departmental assurances about the non-requirement for permission
183 did not always provide participants with reassurance.

184 A difference in viewpoint between whose role it is to develop services, provide solutions, and find or
185 restructure resource seemed apparent between clinic- and non-clinic providing pharmacists.

186 **Clinic structure and processes**

187 *Defined patient cohorts in initial stages*

188 Clinic-providing pharmacists detailed how their role was created to provide a service to a clearly defined
189 cohort of patients, and that they had a clear understanding with their MDT about what patients they
190 would review. Once they became more comfortable with their role, they were provided with further
191 opportunities to take responsibility for an expanded cohort of patients. In some cases, this led to even
192 more resource to continue and expand their outpatient role within their MDT.

193 *Integration within standard patient treatment pathways*

194 All clinic providers could clearly define their MDT outpatient model and how patients were referred to
195 their pharmacist-led clinic. Clinic providers were typically able to detail how their clinic improved the
196 overall service efficiency or effectiveness. In contrast, non-clinic providers provided examples of being
197 uncertain where they fit within the outpatient journey.

198 *Exemplar peers*

199 The clinic providers highlighted the value of collaborating with a network of pharmacists who were
200 already providing a clinic, similar to their own. However, non-clinic providers revealed that without an
201 exemplar they struggled to establish a new clinic, or expand their existing role within their MDT.

202 *Practical and administrative Support*

203 All participants disclosed how their lack of knowledge about the processes for establishing a clinic
204 hindered their progress in implementing them. However, clinic providers described how administrative
205 support from within their MDT allowed them to better manage the administrative tasks and workload
206 associated with their outpatient clinic (e.g. dictation). The biggest physical barrier to clinic provision
207 was the need for clinic space, though the MDT provided this in most cases. The provision of support
208 from other MDT members was viewed as essential by all clinic-providing pharmacists to assist with the
209 progression of their clinic training and integration into the MDT outpatient model.

210 **Additional clinical skills and training**

211 *Prescribing, examination and consultation skills*

212 Most clinic-providing pharmacists acknowledged the benefits of obtaining and developing extra clinical
213 skills and training (e.g. physical examination). However, despite obtaining more additional clinical
214 skills and post-graduate qualifications (see Table 1), the non-clinic providers perceived a need for
215 further clinic-specific skills and training. Others highlighted that until they had obtained their
216 independent prescribing qualification, they were unable to provide the clinic, or were reliant on other
217 MDT members to carry out prescribing activities for their patients.

218 *Mentorship and preceptorship of clinical skills*

219 Clinic-providing pharmacists described the value of having a mentor to support their training. Some
220 recounted shadowing and observing their peers or MDT colleagues who were already running a similar
221 type of clinic, and explained that this allowed them to gain a better understanding of the clinic setting
222 and specialist practice. Others described the benefits of having a preceptor who assessed their individual
223 progress and level of competency, in addition to providing clinical support and reassurance during the
224 earlier stages of their training and clinic provision.

225 **Competing priorities**

226 *Additional resource required*

227 For most non-clinic providers, it was felt that more resource or some kind of “backfill” was essential to
228 allow them the opportunity to expand their inpatient role into the outpatient setting. Many felt that the
229 current staffing within their hospital pharmacy team was insufficient to cover their inpatient workload
230 and commitments; in general, or with reference to specific tasks (e.g. medicines reconciliation,
231 screening discharge prescriptions).

232 Clinic-providing pharmacists detailed how initially they either: had temporary (e.g. funding to provide
233 a clinic 2 days per week) or no extra resource, but managed to demonstrate cost-effectiveness and
234 service efficiency through their outpatient role, which resulted in the provision of extra resource from
235 the institution, and allowed them to further expand their role within the outpatient service.

236 *Prioritisation of Workload*

237 Most non-clinic providers revealed that the inpatient workload was their priority and that it was unclear
238 to them if clinic provision was a priority. Many could not see beyond their inpatient commitments to
239 afford time to explore opportunities within the outpatient setting. Some described a fear of the potential
240 consequences of sacrificing their inpatient workload and were concerned of the potential impact this
241 would have on their pharmacy colleagues or other HCPs based in the clinical areas they cover.

242 Some clinic-providing pharmacists explained that, despite having no extra resource, they managed the

243 inpatient workload and prioritised their outpatient role through informal arrangements with the rest of
244 their hospital pharmacy team (e.g. arranged cover for their workload during their protected clinic time).
245 Others described having flexible working-time arrangements between their MDTs and their pharmacy
246 department to facilitate the expansion of their role into the outpatient setting.

247 **Macro level pharmacy working**

248 Participants commonly realised the need for wide-scale working, beyond their own roles. The approach
249 to this typically differed, however, between clinic-providers and non-clinic-providers.

250 *Whole system working (cross-sector)*

251 Many participants highlighted that they felt there were differences in the opportunities available for
252 different pharmacists in different areas of practice; the most commonly cited example was the greater
253 prioritisation of service development in primary care over the secondary care setting. However, this
254 feeling of inequality was even felt between different pharmacy teams within the same hospital. Given
255 that the NHS is built on a premise of service equity and universality, some non-clinic providers were
256 concerned that the potential outpatient service they could provide in one hospital site would not
257 necessarily be replicable in another. Conversely, clinic-providers described coordinated working across
258 traditional boundaries with pharmacy colleagues from different sectors and locations; utilising shared
259 resources to facilitate expanded outpatient services.

260 *Team-level changes and beyond*

261 A desire for widespread change at the health authority level was pertinent amongst all pharmacists, and
262 changing current practice at individual hospital sites or teams was deemed insufficient to allow the
263 wider progression of the pharmacist role to the outpatient setting. Some participants, whether they
264 provided a clinic or not, expanded on this and highlighted the need for prioritising personal and service
265 development over inpatient workload, and that this needed to be made clearer at the health authority
266 level to facilitate this large-scale change.

267 One proposed solution from many clinic- and non-clinic providers was a greater role for their technician
268 colleagues to take on inpatient-associated tasks that were traditionally only carried out by pharmacists
269 (e.g. medicines reconciliation); two pharmacists explained how they have already integrated clinical
270 technicians within their teams to allow them to prioritise the expansion of their outpatient clinic role.

271 **External stakeholder relationships**

272 *MDT recognition of pharmacist outpatient role*

273 MDT awareness of the potential benefits that a pharmacist could bring to their teams was viewed as
274 essential; all participants explained that without pharmacy promotion, potential clinic-providing
275 opportunities would likely go to other HCPs. Many non-clinic providers desired senior pharmacist
276 support to facilitate these external relationships, and to promote the pharmacist role within the
277 outpatient setting at the executive level. However, despite not yet approaching MDT members
278 themselves, most revealed a belief that MDT members would support the idea of a pharmacist within
279 their outpatient service, and that this was not a barrier. Conversely, clinic-providing pharmacists
280 explained that after promoting their role for a period of time, their MDT is aware of their value to such
281 an extent that they present new potential opportunities directly to them.

282 *Patient recognition of pharmacist outpatient role*

283 Clinic and non-clinic providers discussed the potential benefits that positive patient recognition of the
284 pharmacist can have to enabling new opportunities for clinic provision. Some reported positive informal
285 patient feedback, whilst others revealed patient-reported gaps (e.g. there is currently no pharmacist input
286 to a service that treats a condition which mostly involves medicine prescribing, monitoring and
287 adjustment) in their current service provision by other HCPs, especially in relation to their medicines
288 management

289

290 A visual illustration of how all of these themes relate over time at different stages of clinic provision is
291 shown in Figure 1.

293 **DISCUSSION**

294 **Statement of key findings**

295 Participants in this study described multiple complex overlapping enablers and barriers to clinic
296 provision. These included: clinic prerequisites and requirements, as well as knowledge and support for
297 the practical and clinical aspects of clinic provision; individual factors and competing priorities;
298 pharmacy-team specific factors, from the micro to the macro level; competing priorities; the roles of
299 preceptors, mentors and peers; and relationships with external stakeholders, such as the MDT and
300 patients.

301 Clinic-providing pharmacists frequently revealed the benefits of obtaining several clinic pre-requisites
302 such as: a clear service need, support and resource from senior hospital department staff, a clearly
303 defined cohort of patients to manage, MDT integration and support, administrative support, and
304 protected clinic slots and physical spaces. Globally, these are all established enablers to clinic provision
305 by other HCPs [21, 42, 43], with some of these also potentially aiding the progression of clinical
306 pharmacy services and independent prescribing activities [22, 23, 44, 45].

307 Despite having achieved a greater number of additional clinical skills and post-graduate qualifications,
308 the desire for further skills and training amongst non-clinic providing pharmacists was prominent;
309 indicating that the training provided by current post-graduate courses may be inadequate to overcome
310 certain practical barriers. With participants in our study highlighting the benefits of mentorship and
311 preceptorship; more clinic-specific training and direct supervision which incorporates these, seems a
312 logical approach.

313 Individual factors predominated throughout the interviews, and are widely reported worldwide as
314 barriers to pharmacists progressing their roles, and undertaking clinical activities such as independent
315 prescribing and research [23, 45-49]. Our findings that MDT integration and support gradually
316 addressed the issues of confidence and clinical competency, are also supported by the literature [44-
317 46]. However, as well as at the individual level, participants revealed organisational level features. Non-

318 clinic providers disclosed a perceived need for permission from senior pharmacists and pharmacy
319 services. This is substantiated by existing literature that details a lack of progression in clinical activities
320 carried out by pharmacists without management approval and support [23, 45, 46, 50]. However, in our
321 study there were no formal cases of participants being denied permission; this fatalism has previously
322 been highlighted as a barrier to NHS pharmacists undertaking research [50].

323 The need to overcome barriers with creative solutions that result in the implementation of their
324 outpatient role was evident in our study. This requisite for creative leadership to facilitate clinic
325 provision is not unique to pharmacists [21]. Participants revealed competing individual priorities and
326 perceived differences between different pharmacy teams in hospital- and community-based settings;
327 these issues appear to also hinder the development of hospital-based pharmacy services in other
328 countries [23].

329 Although our inductive analysis was not framed *a-priori* around implementation science, our findings
330 fit well into the five domains described in the Consolidated Framework For Implementation Research
331 [51]; intervention characteristics (e.g. independent prescribing and additional clinical skills), outer
332 setting (e.g. multidisciplinary integration and relationships), inner setting (e.g. department vision,
333 competing priorities, protected time for clinics), individuals (e.g. confidence, locus of control), and the
334 process of implementation (e.g. preceptorship, practical and administrative elements of setting a clinic
335 up). Utilising such frameworks may offer means to realise changes at the macro-level.

336 **Strengths & Weaknesses**

337 This study not only produced qualitative data about the barriers, but also detailed enablers from the
338 actual insights and experiences of participants that succeeded in a system where these barriers are
339 present to now provide clinics routinely as part of their role.

340 This evaluation covered the largest health authority in Scotland, and our purposive sampling strategy
341 enabled us to obtain qualitative data from clinic- and non-clinic providing hospital pharmacists, with a
342 variety of different demographic and professional characteristics [26, 27].

343 There were some limitations. The interviewer (GB) was known in a professional capacity by some
344 participants which may have introduced some response bias. However, the potential benefits of
345 interviewer-respondent familiarity and rapport have been reported, but the effects of this on the quality
346 of data are still not fully understood [52-57]. This study was carried out within one regional health
347 authority and it is unclear if all of these findings would be applicable to other health authorities.

348

349 **Interpretation & Further Research**

350 Our study suggests that individual- or hospital-level changes alone will be insufficient to progress
351 wholesale change. The results raise a broader question; whose job is it to develop new roles and new
352 services, clinicians or organisations/managers? Our study hints that there is not a consensus view in the
353 incumbent workforce and that many individual barriers may be secondary to a systematic discord in the
354 current workforce model as to whose responsibility it is to develop new roles and to take forward new
355 service developments (e.g. where should the locus of control sit?).

356 Scotland is beginning to address this issue through the publication of national pharmacist career
357 pathway review, and the operationalisation of new Royal Pharmaceutical Society professional curricula
358 [58, 59]. These changes will link all pharmacists to an appropriate national curricula, which intends to
359 support the development of clinical skills, including autonomously managing clinical risk, and non-
360 clinical skills, inclusion leadership, service development, education of less experienced colleagues and
361 research/service evaluation [58, 59]. Such curricula are intended to evidence skills application, rather
362 than the acquirement of new knowledge. To increase the likelihood of success with these bold visions,
363 completion of such curricula needs to be linked to career reward and progression [60]. Further research
364 would need to test how to implement, and to what extent pharmacists accept, responsibilities of formal
365 distributed leadership [60]. Broader work is also required within NHS Scotland to define and implement
366 appropriate support-structures [61]. Prospective research should assess the impact of this vision on
367 professional confidence and efficacy, and ultimately outpatient clinic provision.

368 **CONCLUSION**

369 The complex enablers and barriers to hospital pharmacists providing outpatient clinics are multifaceted
370 and will unlikely be resolved by one single intervention. Changes are required at the micro-level (e.g.
371 individual and team) and the macro-level (e.g. institution and health authority). A broader over-arching
372 question of ‘whose job is it to develop new roles and new services’ remains unclear. The forthcoming
373 implementation of new professional curricula may enable pharmacists to overcome the individual and
374 systematic barriers that prevent them from currently progressing the development of outpatient clinic
375 services; prospective research needs to accompany this vision.

376

377 **Acknowledgements:** The authors would like to thank all the pharmacists who participated in this
378 study.

379

380 **Funding:** This research received no specific grant from any funding agency in the public, commercial,
381 or not-for-profit sectors.

382

383 **Conflicts of interest:** None.

384

385 **REFERENCES**

386 1. Pande S, Hiller JE, Nkansah N, *et al.* The effect of pharmacist-provided non-dispensing services on patient
387 outcomes, health service utilisation and costs in low- and middle-income countries. *Cochrane Database Syst*
388 *Rev.* 2013 Feb 28; (2): CD010398. doi: 10.1002/14651858.CD010398. PMID: 23450614.

389 2. Nkansah N, Mostovetsky O, Yu C, *et al.* Effect of outpatient pharmacists' non-dispensing roles on patient
390 outcomes and prescribing patterns. *Cochrane Database Syst Rev.* 2010 Jul 7; (7): CD000336. doi:
391 10.1002/14651858.CD000336.pub2. PMID: 20614422; PMCID: PMC7087444.

392 3. Ryan R, Santesso N, Lowe D, *et al.* Interventions to improve safe and effective medicines use by
393 consumers: an overview of systematic reviews. *Cochrane Database Syst Rev.* 2014 Apr 29; (4): CD007768.
394 doi: 10.1002/14651858.CD007768.pub3. PMID: 24777444; PMCID: PMC6491214.

395 4. Weeks G, George J, Maclure K, *et al.* Non-medical prescribing versus medical prescribing for acute and
396 chronic disease management in primary and secondary care. *Cochrane Database Syst Rev.* 2016 Nov 22; 11
397 (11): CD011227. doi: 10.1002/14651858.CD011227.pub2. PMID: 27873322; PMCID: PMC6464275.

398 5. Poh EW, McArthur A, Stephenson M, *et al.* Effects of pharmacist prescribing on patient outcomes in the
399 hospital setting: a systematic review. *JBI Database System Rev Implement Rep.* 2018 Sep; 16 (9): 1823-
400 1873. doi: 10.11124/JBISRIR-2017-003697. PMID: 30204671.

401 6. Department of Health. Improving Patients' Access to Medicines: A Guide to Implementing Nurse and
402 Pharmacist Independent Prescribing within the NHS in England [internet]. London (UK): Department of
403 Health; 2006 Apr. Available from:
404 https://webarchive.nationalarchives.gov.uk/20130105033522/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4133747.pdf (Accessed: 14 Nov 2020).

406 7. General Pharmaceutical Council. Standards for the education and training of pharmacist independent
407 prescribers [internet]. London (UK): General Pharmaceutical Council; 2019 Jan. Available from:
408 <https://www.pharmacyregulation.org/sites/default/files/document/standards-for-the-education-and-training-of-pharmacist-independent-prescribers-january-19.pdf> (Accessed: 14 Nov 2020).

410 8. O'Brien N, Hoskins C. Pilot of a Pharmacist Independent Prescriber in Orthopaedic Admissions suite
411 (OAS) to support the Enhanced Recovery After Surgery (ERAS) project for patients undergoing Hip and
412 Knee replacement Surgery and to reduce length of stay. UKCPA Joint Poster presentation at the National
413 Conference; 2014 April 4-6; Manchester (UK). Available from: [http://ukclinicalpharmacy.org/wp-](http://ukclinicalpharmacy.org/wp-content/uploads/2017/05/UKCPA-GHP_Conference_Abstacts_April2014.pdf)
414 [content/uploads/2017/05/UKCPA-GHP_Conference_Abstacts_April2014.pdf](http://ukclinicalpharmacy.org/wp-content/uploads/2017/05/UKCPA-GHP_Conference_Abstacts_April2014.pdf) (Accessed: 14 Nov 2020).

- 415 9. Baqir W, Crehan O, Murray R, *et al.* Pharmacist prescribing within a UK NHS hospital trust: nature and
416 extent of prescribing, and prevalence of errors. [Eur J Hosp Pharm](#)~~European Journal of Hospital Pharmacy~~.
417 2014; 22: 79–82. doi: 10.1136/ejpharm-2014-000486.
- 418 10. Rush C, Forsyth P, Moir L, *et al.* Collaborative care with a pharmacist improves optimisation of secondary
419 prevention medication after discharge in patients with left ventricular systolic dysfunction due to acute
420 myocardial infarction. [Eur J Heart Fail](#). ~~European Journal of Heart Failure~~. 2015; 17: S1 (pp 341). doi:
421 10.1002/ejhf.277.
- 422 11. Vaghela T, Ramesh C. Impact of change in practice: pharmacist-led respiratory syncytial virus (RSV)
423 immunoprophylaxis clinic. [Arch Dis Child](#). ~~Archives of Disease in Childhood~~. 2011; 96 (4): e1. doi:
424 10.1136/adc.2011.211243.7.
- 425 12. Scottish Government. Public Health Priorities for Scotland [internet]. Edinburgh (Scotland): The Scottish
426 Government; 2018 Jun. Available from: [https://www.gov.scot/publications/scotlands-public-health-](https://www.gov.scot/publications/scotlands-public-health-priorities/)
427 [priorities/](https://www.gov.scot/publications/scotlands-public-health-priorities/) (Accessed: 14 Nov 2020).
- 428 13. Scottish Government. The Scottish Health Survey 2019 – volume 1: main report [internet]. Edinburgh
429 (Scotland): The Scottish Government; 2020 Sep. Available from:
430 <https://www.gov.scot/publications/scottish-health-survey-2019-volume-1-main-report/> (Accessed: 14 Nov
431 2020).
- 432 14. Information Services Division: Public Health Scotland. Acute hospital activity and NHS Beds Information
433 for Scotland (Annual – Year ending 31 March 2019) [internet]. Edinburgh (Scotland): Public Health
434 Scotland; 2019 Sep. Available from:
435 [https://beta.isdscotland.org/find-publications-and-data/health-services/hospital-care/acute-hospital-activity-](https://beta.isdscotland.org/find-publications-and-data/health-services/hospital-care/acute-hospital-activity-and-nhs-beds-information-annual/10-september-2019/)
436 [and-nhs-beds-information-annual/10-september-2019/](https://beta.isdscotland.org/find-publications-and-data/health-services/hospital-care/acute-hospital-activity-and-nhs-beds-information-annual/10-september-2019/) (Accessed: 29 Nov 2020).
- 437 15. Scottish Government. A National Clinical Strategy For Scotland [internet]. Edinburgh (Scotland): The
438 Scottish Government; 2016 Feb. Available from: [https://www.gov.scot/publications/national-clinical-](https://www.gov.scot/publications/national-clinical-strategy-scotland/)
439 [strategy-scotland/](https://www.gov.scot/publications/national-clinical-strategy-scotland/) (Accessed: 14 Nov 2020).
- 440 16. Royal College of Physicians. Outpatients: The future - adding value through sustainability [internet].
441 London (UK): Royal College of Physicians; 2018. Available from:
442 <https://www.rcplondon.ac.uk/projects/outputs/outpatients-future-adding-value-through-sustainability>
443 (Accessed: 14 Nov 2020).

- 444 17. Scottish Government. The Modern Outpatient: A Collaborative Approach 2017-2020 [internet]. Edinburgh
445 (Scotland): The Scottish Government; 2016 Dec. Available from:
446 <https://www.gov.scot/publications/modern-outpatient-collaborative-approach-2017-2020/> (Accessed: 14
447 Nov 2020).
- 448 18. Scottish Government. Achieving Excellence in Pharmaceutical Care: A Strategy for Scotland [internet].
449 Edinburgh (Scotland): The Scottish Government; 2017 Aug. Available from:
450 <http://www.gov.scot/Publications/2017/08/4589> (Accessed: 14 Nov 2020).
- 451 19. Scottish Government. A Plan For Scotland: 2016-17 [internet]. Edinburgh (Scotland): The Scottish
452 Government; 2016 Sep. Available from: <https://www2.gov.scot/Resource/0050/00505210.pdf> (Accessed:
453 14 Nov 2020).
- 454 20. Forsyth P, Moir L, Speirits I, *et al.* Improving medication optimisation in left ventricular systolic
455 dysfunction after acute myocardial infarction. *BMJ Open Qual.* 2019; 8 (3): e000676. doi: 10.1136/bmjoq-
456 2019-000676. PMID: 31544164; PMCID: PMC6730630.
- 457 21. Haines KJ, McPeake J, Hibbert E, *et al.* Enablers and Barriers to Implementing ICU Follow-Up Clinics and
458 Peer Support Groups Following Critical Illness: The Thrive Collaboratives. *Crit Care Med.* 2019 Sep; 47
459 (9): 1194-1200. doi: 10.1097/CCM.0000000000003818. PMID: 31241499; PMCID: PMC6699486.
- 460 22. Salgado TM, Moles R, Benrimoj SI, *et al.* Exploring the role of renal pharmacists in outpatient dialysis
461 centres: a qualitative study. *Int J Clin Pharm.* 2012 Aug; 34 (4): 569-578. doi: 10.1007/s11096-012-9645-z.
- 462 23. Brazinha I, Fernandez-Llimos F. Barriers to the implementation of advanced clinical pharmacy services at
463 Portuguese hospitals. *Int J Clin Pharm.* 2014 Oct; 36 (5): 1031-1038. doi: 10.1007/s11096-014-9991-0.
- 464 24. NHS Greater Glasgow and Clyde [internet]. Our hospitals: Our Hospitals and Sites. Available from:
465 <https://www.nhsggc.scot/hospitals-services/our-hospitals/> (Accessed: 17 May 2022).
- 466 25. Scottish Government. Scottish Index of Multiple Deprivation 2020: introduction [internet]. Edinburgh
467 (Scotland): Scottish Government; 2020 Jan. Available from: [https://www.gov.scot/publications/scottish-
468 index-multiple-deprivation-2020/](https://www.gov.scot/publications/scottish-index-multiple-deprivation-2020/) (Accessed: 08 Dec 2020).
- 469 26. Etikan I, Musa SA, Alkassim RS. Comparison of convenience sampling and purposive sampling. *Am J*
470 *Theor Appl Stat.* 2016; 5: 1-4. doi: 10.11648/j.ajtas.20160501.11
- 471 27. Ritchie J, Lewis J, Elam G, Tennant R, Rahim N. Chapter 5: Designing and Selecting Samples. In: Ritchie
472 J, Lewis J, McNaughton Nicolls C, Ormston R, editors. *Qualitative Research Practice: A Guide for Social*
473 *Science Students and Researchers*, 2nd edition. London (UK): SAGE Publications; 2013. p 111-119.

- 474 28. Adler PA, Adler P. Limitations to sample pools. In: Baker SE, Edwards R, Doidge M, editors. National
475 centre of research review paper: how many qualitative interviews is enough?: expert voice and early career
476 reflections on sampling and cases in qualitative research. Southampton (UK): National Centre for Research
477 Methods; 2012. p 10.
- 478 29. Guest G, Bunce A, Johnson L. How Many Interviews Are Enough?: An Experiment with Data Saturation
479 and Variability. *Field Methods*. 2006; 18 (1), 59–82. doi: 10.1177/1525822X05279903.
- 480 30. Namey E, Guest G, McKenna K, *et al*. Evaluating Bang for the Buck: A Cost-Effectiveness Comparison
481 Between Individual Interviews and Focus Groups Based on Thematic Saturation Levels. [American Journal
482 of Evaluation-Am J Eval](#). 2016; 37 (3), 425–440. doi: 10.1177/1098214016630406.
- 483 31. Microsoft [Internet]. Microsoft 365: Microsoft Teams. Available from: [https://www.microsoft.com/en-
484 gb/microsoft-365/microsoft-teams/group-chat-software](https://www.microsoft.com/en-
484 gb/microsoft-365/microsoft-teams/group-chat-software) (Accessed: 08 Dec 2020).
- 485 32. QSR International [Internet]. NVivo: Qualitative Data Analysis. Available from:
486 <https://www.qsrinternational.com/nvivo-qualitative-data-analysis-software/about/nvivo> (Accessed: 08 Dec
487 2020).
- 488 33. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol*. 2006; 3: 77-101. doi:
489 10.1191/1478088706qp063oa.
- 490 34. Nowell LS, Norris JM, White DE, *et al* J. Thematic Analysis: Striving to Meet the Trustworthiness Criteria.
491 [International Journal of Qualitative Methods-Int J Qual Methods](#). 2017; 16: 1-13. doi:
492 10.1177/1609406917733847.
- 493 35. DeSantis L, Ugarriza DN. The concept of theme as used in qualitative nursing research. *West J Nurs Res*.
494 2000 Apr; 22 (3): 351-372. doi: 10.1177/019394590002200308. PMID: 10804897.
- 495 36. Joffe H. Chapter 15: Thematic Analysis. In: Harper D, Thompson A, editors. *Qualitative Research Methods
496 in Mental Health and Psychotherapy: A Guide for Students and Practitioners*. Chichester (UK): Wiley-
497 Blackwell; 2012. p 209-224.
- 498 37. Webster S, Lewis J, Brown A. Chapter 4: Ethical Considerations in Qualitative Research. In: Ritchie J,
499 Lewis J, McNaughton Nicolls C, Ormston R, editors. *Qualitative Research Practice: A Guide for Social
500 Science Students and Researchers*, 2nd edition. London (UK): SAGE Publications; 2013. p 77-110.
- 501 38. Côté L, Turgeon J. Appraising qualitative research articles in medicine and medical education. *Med Teach*.
502 2005; 27 (1): 71-75. doi: 10.1080/01421590400016308. PMID: 16147774.

- 503 39. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item
504 checklist for interviews and focus groups. *Int J Qual Health Care*. 2007; 19 (6): 349–357. doi:
505 10.1093/intqhc/mzm042.
- 506 40. Scottish Terms and Conditions Committee (STAC). Proposal for Reform of Agenda for Change in NHS
507 Scotland (Framework Agreement) [internet]. 2018 Aug. Available from: [https://www.stac.scot.nhs.uk/wp-](https://www.stac.scot.nhs.uk/wp-content/uploads/Test.pdf)
508 [content/uploads/Test.pdf](https://www.stac.scot.nhs.uk/wp-content/uploads/Test.pdf) (Accessed on 6 Dec 2020).
- 509 41. General Medical Council [internet]. GMC approved postgraduate curricula. Available from:
510 <https://www.gmc-uk.org/education/standards-guidance-and-curricula/curricula> (Accessed: 29 Nov 2020).
- 511 42. Hatchett R. Nurse-led clinics: 10 essential steps to setting up a service. *Nursing Times*. 2008; 104 (4): 62-
512 64.
- 513 43. Berei T, Forsyth P, Balakumaran K, *et al*. Implementing Nonphysician Provider Guideline-Directed
514 Medical Therapy Heart Failure Clinics: A Multi-National Imperative. *J Card Fail*. 2021; 27 (8): 896-906.
515 doi: 10.1016/j.cardfail.2021.06.001. PMID: 34364666.
- 516 44. Fisher J, Kinnear M, Reid F, *et al*. What supports hospital pharmacist prescribing in Scotland? – A mixed
517 methods, exploratory sequential study. [Research in Social and Administrative Pharmacy–Res Social Adm](#)
518 [Pharm](#). 2018; 14: 488-497. doi: 10.1016/j.sapharm.2017.06.007.
- 519 45. Graham-Clarke E, Rushton A, Noblet T, *et al*. Facilitators and barriers to non-medical prescribing - A
520 systematic review and thematic synthesis. *PLoS One*. 2018 Apr; 13 (4): e0196471. doi:
521 10.1371/journal.pone.0196471. PMID: 29709006; PMCID: PMC5927440.
- 522 46. General Pharmaceutical Council. Prescribers Survey Report [internet]. London (UK): General
523 Pharmaceutical Council; 2016 May. Available from:
524 [https://www.pharmacyregulation.org/sites/default/files/document/gphc_prescribers_survey_report-may-](https://www.pharmacyregulation.org/sites/default/files/document/gphc_prescribers_survey_report-may-2016.pdf)
525 [2016.pdf](https://www.pharmacyregulation.org/sites/default/files/document/gphc_prescribers_survey_report-may-2016.pdf) (Accessed: 14 Nov 2020).
- 526 47. Frankel GE, Austin Z. Responsibility and confidence: Identifying barriers to advanced pharmacy practice.
527 *Can Pharm J (Ott)*. 2013 May; 146 (3): 155-161. doi: 10.1177/1715163513487309.
- 528 48. Rosenthal M, Austin Z, Tsuyuki RT. Barriers to pharmacy practice change: Is it our nature or nurture? *Can*
529 *Pharm J (Ott)*. 2016 Nov; 149 (6): 317-319. doi: 10.1177/1715163516672832.
- 530 49. Rosenthal M, Austin Z, Tsuyuki RT. Are Pharmacists the Ultimate Barrier to Pharmacy Practice
531 Change? *Canadian Pharmacists Journal / Revue des Pharmaciens du Canada*. 2010; 143 (1): 37-42.
532 doi:10.3821/1913-701X-143.1.37.

- 533 50. Lowrie R, Morrison G, Lees R, *et al.* Research is 'a step into the unknown': an exploration of pharmacists'
534 perceptions of factors impacting on research participation in the NHS. *BMJ Open*. 2015 Dec 30; 5 (12):
535 e009180. doi: 10.1136/bmjopen-2015-009180.
- 536 51. Damschroder LJ., Aron DC., Keith RE. *et al.* Fostering implementation of health services research findings
537 into practice: a consolidated framework for advancing implementation science. *Implementation Sci*. 2009; 4
538 (50). doi: 10.1186/1748-5908-4-50.
- 539 52. Mitchell K, Wellings K, Elam G, *et al.* How can we facilitate reliable reporting in surveys of sexual
540 behaviour? Evidence from qualitative research. *Culture, Health and Sexuality*. 2007; 9 (5): 519-531. doi:
541 10.1080/13691050701432561.
- 542 53. Tu SH, Liao PS. Social Distance, Respondent Cooperation and Item Nonresponse in Sex Survey. *Quality*
543 *and Quantity*. 2007; 41: 177-199. doi: 10.1007/s11135-007-9088-0.
- 544 54. Rodriguez LA, Sana M, Sisk B. Self-administered Questions and Interviewer-Respondent Familiarity. *Field*
545 *Methods*. 2015; 27 (2): 163-181. doi: 10.1177/1525822X14549315.
- 546 55. Rossier C. Estimating induced abortion rates: A review. [Studies in Family Planning- Stud Fam Plann](#). 2003;
547 34 (2): 87-102.
548 doi: 10.1111/j.1728-4465.2003.00087.x.
- 549 56. Weinreb AA, Sana M, Stecklov G. A test of the stranger-interviewer norm in the Dominican Republic.
550 *Popul Stud (Camb)*. 2016; 70 (1): 73-92. doi: 10.1080/00324728.2016.1139740.
- 551 57. Stecklov G, Weinreb AA, Sana M. Family Planning for Strangers: An Experiment on the Validity of
552 Reported Contraceptive Use. *PLoS One*. 2015; 10 (8): e0136972. doi: 10.1371/journal.pone.0136972.
553 PMID: 26322898; PMCID: PMC4554992.
- 554 58. NHS Education for Scotland. Pharmacist Career Framework Review – Report of the Review Advisory
555 Group [internet]. Edinburgh (Scotland): NHS Education for Scotland; 2020 Sep. Available from:
556 https://www.nes.scot.nhs.uk/media/vzahxc4w/final-pharmacy-pg-framework-review_v1-1.pdf (Accessed
557 14 Jan 2021).
- 558 59. Royal Pharmaceutical Society. The RPS Advanced Pharmacy Framework (APF) [internet]. London (UK):
559 Royal Pharmaceutical Society; 2013. Available from:
560 [https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/Frameworks/RPS%20A
561 dvanced%20Pharmacy%20Framework.pdf \(Accessed 14 Jan 2021\).](https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/Frameworks/RPS%20Advanced%20Pharmacy%20Framework.pdf)

- 562 60. Martin G, Beech N, MacIntosh R, *et al.* Potential challenges facing distributed leadership in health care:
563 evidence from the UK National Health Service. *Sociol Health Illn.* 2015 Jan;37(1): 14-29. doi:
564 10.1111/1467-9566.12171. Epub 2014 Dec 20. PMID: 25529349.
- 565 61. Forsyth P, Rushworth GF. Advanced pharmacist practice: where is the United Kingdom in pursuit of this
566 'Brave New World'?. *Int J Clin Pharm.* 2021 May 15. <https://doi.org/10.1007/s11096-021-01276-5>. Epub
567 ahead of print. PMID: 33991288.
- 568

Table 1. Characteristics of participating pharmacists

Variables	Pharmacists who provided a clinic (n = 8)	Pharmacists who did not provide a clinic (n = 8)	Both cohorts combined (n = 16)
Participants	P1, P2, P4, P5, P6, P8, P10, P13	P3, P7, P9, P11, P12, P14, P15, P16	
Age, years Median (IQR)	38.5 (31.0 – 42.5)	35.0 (29.5 – 39.5)	38.0 (30.5 – 40.0)
Gender, n			
Female	5	6	11
Male	3	2	5
Time qualified as a pharmacist, years Median (IQR)	16.0 (8.0 – 20.5)	12.0 (6.5 – 16.5)	15.5 (7.5 – 18.0)
Time practising as a hospital pharmacist, years Median (IQR)	13.0 (8.0 – 19.5)	12.0 (6.5 – 16.0)	12.5 (7.5 – 16.5)
Achieved an Independent Prescribing qualification, n	8	7	15
Time qualified as an Independent Prescriber, years Median (IQR)	3.8 (2.0 – 8.3)	2.1 (0.3 – 3.0)	3.0 (0.8 – 4.5)
NHS Pay Grade/ Banding ^a , n			
Band 6	0	1	1
Band 7	2	3	5
Band 8a	5	3	8
Band 8b	1	1	2
Working time per week ^b , hours Median (IQR)	37.5 (32.8 – 37.5)	35.75 (30.0 – 37.5)	37.5 (30.0 – 37.5)
Frequency of rotation through more than one specialty in their current role ^c , n			
Doesn't occur in current role	7	4	11
Daily	0	3	3
Weekly	1	0	1
Monthly	0	1	1
Additional post-graduate qualifications, n			
Post-graduate diploma	4	5	9
Masters degree	4	5	9
Additional clinical skills/training ^d , n			
Clinical skills	5	6	11
Consultation skills	2	3	5
Advanced clinical assessment	1	0	1
Venepuncture	1	0	1

IQR = Interquartile Range (Q1 – Q3); NHS = National Health Service.

^aNHS Pay Grade / Banding as specified by the NHS Scotland – Scottish Terms & Conditions Committee [40].

^bStandard full time working hours in NHS Scotland are 37.5 hours per week.

^cSpecialties as defined by the General Medical Council [41].

^dAdditional skills/training were viewed by participants as being achieved following the completion of a nationally recognised course.

Table 2. Illustrative quotes from interviews highlighting themes and sub-themes


Theme	Sub-Theme	Exemplar Enabler Quote	Exemplar Barrier Quote
Clinical or service need	N/A	'... [the clinic] really worked and happened quickly for me because the directorate* needed it to happen.' (P5)	No examples given by participants
Individual factors	Personal motivation	'I think it [providing a clinic] would give people a huge sense of job satisfaction as well... it is something I am definitely keen to do in the near future.' (P11)	No examples given by participants
	Confidence with Risk	'I had a lot of experience of working with inpatient cardiology; so, I had a pretty good understanding of the background for medicines and treatment rationale...it's like anything, once you do it [the clinic] long enough that level of anxiety or trepidation decreases as you become more confident and familiar with the processes.' (P10)	Lack of confidence in clinical decision making: '...but you won't have that security because you'll have to make the decisions all by yourself.' (P12) Fear of the potential clinical risks: 'I am still actually quite terrified of being alone with a patient, within a room.' (P4)
	Locus of Control	Internal Locus of Control: 'I feel you really have to push the doors open yourself because things aren't going to come for you. You've got to show the value of a pharmacy service because nobody is going to come up to you and say, "Here's a big pool of money, can you set up a clinic?'" (P5) Leadership leading to creative solutions: '...we had put a model together for a clinic and with the MCN, everybody had agreed that there was a need for pharmacist input and we went out and got our own money for it...we put in a grant application [to a drug company] and there was money given for technicians, as well as pharmacist's time.' (P14)	External Locus of Control: 'How can that be done without getting permission...?' (P15) Department providing assurances on permission does not always result in reassurance: 'We've had quite a clear message from the leads in pharmacy that we don't need permission to do something but I think that this is not true.' (P13) Needs solutions & resource provided directly: 'So we did approach our senior pharmacy team and asked if we could do this and we were told that we didn't have the money to pay for it.' (P16)
Clinic structure and processes	Defined Patient Cohorts in Initial Stages	'When I first started, I only saw rheumatoid arthritis patients but I now see all different types of patients.' (P6)	No examples given by participants
	Integration within standard patient treatment pathways	'she [consultant] really had a vision for where the pharmacist would fit into her clinic, and it was quite a pre-defined role that was easier to train towards because she knew what the goal was for the pharmacist...' (P2)	'How do we know where the gaps are in the outpatient service, and where does the pharmacist fit?' (P7)
	Exemplar Peers	Exemplar Peer Present: '...he [external pharmacist peer] was trying to establish the service, along with one of the consultants. So, I was lucky in a sense that there was an established service within the [hospital] which I could tap into.' (P10)	Exemplar Peer Absent: '...but it's just not something so far that has historical precedence. So, that in itself is a barrier. Just that these things don't exist yet.' (P3)
	Practical and administrative Support	Increasing knowledge of, and gaining administrative support for, the practical elements: 'It was mostly just the technical side of things I needed help with like, "Will I get a space? How do patients get appointed to my clinic? Will someone be able to do my dictations?" ... I spoke to the administration manager and she arranged for an assigned audio typist who now does all my dictations...just someone showing you how to work a Dictaphone and how to approve your clinic letters is important.' (P5)	Lack of knowledge of the clinic processes hindering its establishment: 'I guess, I was maybe a bit too enthusiastic and naive in the beginning by thinking, "this is such a fantastic opportunity, and I can't wait to get stuck in" ... but I don't think you could start a clinic without considering all these [practical] aspects...' (P16). Need for administrative support: '...I know it is very time consuming to do dictations or to do your own letters. So, we need to ensure we do have admin support for that, and I think that these are things that even the doctors struggle with at the moment within our service.' (P16)
Additional clinical skills & training	Prescribing, examination, and consultation skills	'...during my prescribing course, I've picked up all the skills for clinical assessment and consultation through those [NHS Education for Scotland] study days and then I went on to do an advanced clinical skills assessment course after I qualified... over time, definitely with practice and experience, picking up more, seeing more patients, that has all helped me to provide the service more confidently.' (P8)	Need for independent prescribing: 'I wasn't a prescriber when I first started doing this clinic...and it meant I was having to get medics or other pharmacists to write all my prescriptions for me after seeing patients in clinic.' (P1) Need for learning & updating clinical skills: 'So that [examining patients] would be completely new to me, and doing face to face consultations. So, I would need to go on courses for that, and even expand on my IP.' (P7)
	Mentorship and preceptorship of clinical skills	'...at the start; I was doing the clinic with the regular pharmacist being on at the same time in another room. I now feel more comfortable having to do that in that setting now.' (P8)	No examples given by participants

* = this refers to the local service

Table 2. Illustrative quotes from interviews highlighting themes and sub-themes (continued)

Competing priorities	Additional resource required	Using temporary resource to demonstrate cost-effectiveness leading to extra resource to expand outpatient role further: 'When I first started, I was only two days a week, and then we did quite a lot of work around the tapering and the cost-savings and at that point I was offered a third day [external MDT funding] because finance said from the savings made, they could offer me a third day'. (P6)	'...there would need to be some sort of backfill; that's the basic problem because we're a small team who cover a large unit; the same as everywhere I'm sure.' (P13) 'I think sometimes we barely even fulfil our inpatient commitments let alone to get out into resource centres to start setting up clinics.' (P9) 'I think it's probably due to the challenges of staffing and because of the staffing this means that people worry about the inpatient service before they even think about new service developments.' (P11)
	Prioritisation of Workload	Making informal arrangements with the pharmacy team prioritise outpatient role development: '...when you had your clinic day you just kind of had to build in cover, from your team. So, depending on where I was, someone would be able to cover where I was or what I was meant to be doing that afternoon, and vice versa.' (P4)	'I suppose fundamentally the most critical thing is ward-based duties such as: urgent clinical queries and discharge prescriptions because that has to happen for the maintenance of basic hospital.' (P3) Fear of the consequences if the inpatient workload is perceived to have been sacrificed: 'Because if I'm pulled from a clinic to do my other roles there's nobody to fill that and that would impact my colleagues, it'll impact patient care like for example, confirming meds and all that kind of thing'. (P13)
Macro level pharmacy working	Whole System Working (Cross-sector)	Whole-System working present: "there was, eh, agreement that there would be some appointments across [the health authority] which would have a split component of primary care and acute..." (P10)	Whole-System working absent: '...I am just maybe a bit bitter that the primary care pharmacists are getting to do [clinics] because that is something I wanted to do at one point'. (P9)
	Team-level changes and beyond	Changed other aspects of the team to facilitate outpatient role: '...we've moved a lot of the work on to the technicians' role, where we can, to be able to free up pharmacist time. So, I think we're more efficient now than we used to be with the pharmacist time.' (P1)	Believes Change Needs to be Beyond Their Level of Scope: 'I think there needs to be a significant overhaul ... in the way that we operate because there is limited sustainability and wiggle-room for conducting outpatient clinics. ... it's bigger than just being able to reshuffle individual pharmacy departments in order to have pharmacists introduce 1 or 2 new clinics ...' (P3)
External stakeholder relationships	MDT recognition of pharmacist outpatient role	Positive MDT relationships resulting in more opportunities to progress outpatient role: '...they [MDT] were trying to find a way that I could help their service even more and they needed times freed up for them to take on more acute clinics and patient assessment clinics, and it made sense for a pharmacist to do the therapeutic drug monitoring.' (P6)	Under-developed MDT Relationships Blocking Progress: 'I think there's a lack of a recognition or appreciation for what a pharmacist's role is, particularly within acute care. I think a lot of people see us as some sort of 'prescription provider' rather than an advisory or patient management service....' (P15)
	Patient recognition of pharmacist outpatient role	Positive patient feedback after experiencing a pharmacist-led clinic: 'Yeah, the patients love it. They think it's great. They love having someone who will talk to them about what's going to happen with their medicines.' (P13)	No examples given by participants

IP = independent prescribing; MCN = managed clinical network (NB- this is a local multi-professional service development committee); MDT = multidisciplinary team



IP = Independent Prescribing

Figure 1: Enablers (green) and barriers (pink) to the provision of outpatient clinics by hospital pharmacists

[Click here to view linked References](#)

1 **ABSTRACT**

2 **Background:** With increasing demands on the National Health Service (NHS), Scottish Government-
3 led pharmacy strategy has prioritised the development and expansion of outpatient services. Pharmacist-
4 led outpatient clinics have been shown to reduce hospital admissions and improve patient outcomes.
5 However, expanding these contemporary models of care has proved challenging, and there are few
6 qualitative data about the factors affecting the provision of these.

7 **Aim:** This study aimed to explore the enablers and barriers to hospital pharmacists providing outpatient
8 clinics within the largest health authority in Scotland, NHS Greater Glasgow & Clyde (NHSGGC).

9 **Method:** Between August and October 2020, one-to-one semi-structured interviews were conducted
10 virtually using the videoconferencing platform Microsoft Teams[®], with NHSGGC hospital pharmacists
11 who did or did not provide clinics. Audio- and video-recordings of the interviews were transcribed
12 verbatim and underwent thematic analysis.

13 **Results:** 16 hospital pharmacists were interviewed; 50% were clinic providers and 50% were not.
14 Analysis generated seven themes: clinical or service need, individual factors, clinic structure and
15 processes, additional clinical skills and training, competing priorities, macro-level pharmacy working,
16 and external stakeholder relationships. Many of these were interdependent and had the potential to be
17 an enabler or a barrier to clinic provision, depending on the context or individual.

18 **Conclusion:** The enablers and barriers to hospital pharmacists providing outpatient clinics are
19 multifaceted, incorporating individual, systematic and professional factors. The implementation of new
20 national professional curricula may help address many of these factors, however prospective research
21 needs to accompany this vision.

22

23 **Impact of findings on practice:**

- 24 • The barriers and enablers to the provision of a pharmacist-led outpatient clinic described in this
25 study provide a basis for better understanding the factors contributing to the inertia in hospital
26 pharmacist-led clinic formation and expansion.
- 27 • A broader over-arching question of ‘whose job is it to develop new roles and new services’
28 remains unclear from this study.
- 29 • The implementation of new professional curricula may offer potential solutions by supporting
30 both the development of clinical skills, including autonomously managing clinical risk, and
31 non-clinical skills, inclusion leadership, and service development.
- 32 • Future research should evaluate the impact of such an approach and implementation science
33 frameworks may also offer additional means to realise this change at the macro-level.

34 INTRODUCTION

35 Day-to-day roles of pharmacists worldwide have developed over the last thirty years beyond traditional
36 dispensing roles, to now also include tasks relating to medication review, optimisation, and monitoring
37 [1]; such roles are known to improve patient outcomes and treatment goals [2, 3]. Additionally, in many
38 countries pharmacists have been provided with the legal premise to prescribe medicines; and there is
39 growing evidence that the effectiveness and safety of autonomous non-medical prescribers, including
40 pharmacists, are comparable to those delivered by medical prescribers in a variety of clinical settings
41 [4, 5].

42 United Kingdom (UK) legislation has enabled pharmacists to become independent prescribers upon
43 successful completion of an accredited course; this usually consists of university-based taught
44 components and experiential based learning [6, 7]. Pharmacist Independent Prescribers (PIPs) have
45 demonstrated their benefits for inpatients whilst working in the acute hospital-based setting [8, 9].
46 However through clinic provision, PIPs have also shown their value for outpatients by optimising
47 medicines with known prognostic importance [10, 11]. In Scotland, an increasingly elderly and multi-
48 morbid population pose sustainability challenges to the National Health Service (NHS), requiring a
49 modernisation of the multidisciplinary skill mix and sector of care in which care is delivered [12-17].

50 Scottish Government pharmacy strategy has prioritised utilising the expertise of pharmacists to improve
51 the delivery of services, such as outpatient services and clinics [18]. For hospital pharmacists, a major
52 component of these services is the provision of outpatient duties which encompasses the greater use of
53 PIPs in specialist clinics within both community- and hospital-based settings. [18, 19]. Exemplar
54 models of pharmacist-led clinics utilising advanced skills, such as clinical examination and
55 venepuncture, and independent prescribing (IP) qualification, in specialties like cardiology, have
56 produced measurable benefits [20]. However, anecdotal evidence suggests the expansion of these clinic
57 models into other specialities is limited.

58 There appears to be few worldwide qualitative data about the enablers and barriers to the provision of
59 hospital-based pharmacist-led clinics which is perhaps indicative of how this specialist outpatient role
60 is still in its relative infancy. Despite including pharmacists, findings from a tri-continental study
61 designed to determine the enabler and barriers to hospital-based clinicians establishing post-ICU clinics
62 are limited by their aggregation with that of other healthcare professionals (HCPs), meaning pharmacist-
63 specific enablers and barriers are non-extractable [21]. Other exploratory studies only address the
64 behavioural intentions and expectations of hospital pharmacists potentially expanding their services,
65 with no practical observations and information about service expansions and provision [22, 23].

66 The rationale for this new study was to provide findings that would help inform future local practical
67 implementation strategies for scaling up pharmacists involvement in outpatient clinics, in line with
68 government policy.

69

70 **Aim**

71 This study aimed to explore the enablers and barriers to hospital pharmacists providing outpatient
72 clinics within the largest health authority in NHS Scotland.

73

74 **Ethics approval**

75 The NHS West of Scotland Research Ethics Service Scientific Officer advised that ethical review was
76 not required, on the basis that this study was a service evaluation aiming to deliver government strategy
77 [18]. Approval was obtained, from local governance teams within the health authority, as this study
78 formed part of a wider pharmacy service evaluation.

79

80 **METHOD**

81 **Setting**

82 This study was conducted within NHS Greater Glasgow & Clyde (NHSGGC), the largest autonomous
83 regional health authority in Scotland which provides healthcare to a population of 1.14 million residents
84 [24]. 34% of the most socially and economically deprived areas in Scotland are within the NHSGGC
85 authority [25]. Approximately, 170 pharmacists work across nine hospitals in NHSGGC.

86 **Sampling**

87 Our purposive sampling strategy aimed to recruit pharmacists working within different hospital sites
88 and specialties (e.g. cardiology, oncology, mental health), as well as different levels of hospital and
89 clinic experience [26, 27]. A sample of between 12-20 participants was estimated to potentially achieve
90 data saturation [27-30], whilst we intended to have an equal number of hospital pharmacists who
91 provided, and did not provide, an outpatient clinic. The intended goal of the sample was to provide a
92 breadth of experiences about both the enablers and barriers to outpatient clinic provision.

93 Participant inclusion criteria were permanent or fixed-term employed hospital pharmacists of any level,
94 pay grade, or seniority; who worked in any of the nine hospital sites within NHSGGC [24]. Exclusion
95 criteria included: those on maternity/paternity or sick leave at the time of the study; and the researchers,
96 who were pharmacists, involved in the study. Additionally, pharmacists with less than two years post-
97 registration experience were excluded since they would have been in an early career training position
98 and would be ineligible to gain the additional qualifications (e.g. IP) and experience that are needed to
99 potentially provide a pharmacist-led outpatient clinic [6, 7].

100 **Participant recruitment**

101 A participant information leaflet was disseminated in an internal email in February 2020 by the lead
102 pharmacist for all hospital pharmacists within NHSGGC; a reminder email was sent two weeks later.
103 All interested participants were invited to contact the lead author by email or telephone, who issued

104 consent forms that were completed and returned by email or post. No incentives were offered for
105 participation.

106 **Data collection and handling**

107 Prior to the interviews, two semi-structured interview schedules (one for those who provided
108 pharmacist-led clinics and one for those who did not) were developed (GB, PF) based on the aims of
109 the study. The schedule were then piloted on one independent pharmacist with four months experience
110 of outpatient service provision, modified and developed for use in the main study (see Supplementary
111 File); these pilot interview data were excluded from the study. Due to the COVID-19 pandemic,
112 interview dates were postponed and took place between August and October 2020. At this point each
113 participant was contacted and invited to participate in an online interview using the videoconferencing
114 platform Microsoft Teams® [31]. At the interview, each participant reaffirmed their consent verbally
115 and were informed that the main purpose of the interview was to explore their own views and
116 experiences on clinic provision, and to describe factors that enabled or prevented them from doing this.
117 All interviews lasted between 15-30 minutes, and were video-recorded; these interviews were
118 subsequently transcribed in verbatim and anonymised (GB). These transcripts were then accuracy
119 checked by an independent staff member who did not take part in the study. All electronic data were
120 stored on encrypted and password protected NHS computers. After transcription and validation, all
121 recordings were deleted.

122 **Data analysis**

123 Both coders (GB and PF) were male pharmacists, with a range of experience from 6 to 19 years working
124 in hospital and community-based pharmacy respectively. All transcripts were uploaded onto the
125 qualitative data analysis software NVivo 12.0 (QSR International Pty Ltd.) [32]. All transcribed data
126 underwent thematic analysis using Braun and Clarke's recommended six phases [33, 34]. After
127 familiarisation with the raw transcript data, and with a primary focus on the study aim, an inductive
128 approach was used to segment the data into meaningful categories and descriptors (i.e. generating initial
129 codes). One quarter (n=4) of all transcriptions were independently coded (GB and PF), with a random

130 number generator used to select transcripts. From this, a preliminary coding scheme was produced, and
131 applied, across all past and future interviews; transcripts were reviewed continuously with constant
132 comparisons made between the generated codes and the data to allow the incorporation of consistent
133 and differing responses (GB). Patterns of this coded data were collated into broader concepts which
134 linked them together (i.e. themes) [33-35]. The derivation, review, and refinement of themes were
135 discussed regularly (GB and PF), and continued until each theme was defined and had a clear narrative
136 that was relevant to the aim of this study. Analysis continued concurrently with further participant
137 recruitment until data saturation was achieved; further participant recruitment stopped at this stage [33,
138 36]. Once all interviews were included, and to provide an external check on the data and analysis
139 process, these themes and sub-themes were critiqued and validated by an experienced qualitative
140 research associate (ED) [34, 37, 38]. Differences in interpretation were resolved by consensus; both
141 semantic and latent themes, with sub-themes, emerged from the data. The reporting of this study
142 conforms to the consolidated criteria for reporting qualitative studies (COREQ) guidelines [39].

143

144 **RESULTS**

145 Data saturation was achieved after 16 hospital pharmacists were interviewed; their characteristics are
146 presented in Table 1. Most participants were female (n=11) and median age was 38 years. Other
147 professional and demographic characteristics were broadly similar between the clinic- and non-clinic-
148 providing pharmacist cohorts. Analysis generated seven themes relating to enablers and barriers; many
149 of these were interdependent and had the potential to be an enabler or a barrier to clinic provision,
150 depending on the context or individual. A narrative of each theme and sub-theme is detailed below and
151 illustrative quotes for each are presented in Table 2.

152 **Clinical or service need**

153 Most pharmacists providing an outpatient clinic described its establishment following an increased
154 service or clinical demand. Examples of clinical demands were: the need for the therapeutic monitoring
155 of medicines, post-discharge medication optimisation or patients requiring consideration for a newly
156 approved medicine.

157 **Individual factors**

158 *Personal motivation*

159 All participants cited a personal motivation to progress their career and achieve greater job satisfaction
160 through clinic provision. However, confidence and a locus of control frequently regulated their ability
161 to achieve this.

162 *Confidence with Risk*

163 Limited experience in the clinic environment was a major obstacle, with most participants disclosing
164 an apprehension about the potential clinical risks associated with the increased responsibility of the
165 outpatient role. Others revealed a perceived “fear of the unknown” associated with some aspects of
166 clinic provision. Examples included: physical patient assessment, being left alone in the clinic room
167 with a patient, or having to unexpectedly manage a very unwell or complicated patient. However, all

168 clinic-providing pharmacists stated that these initial anxieties faded over time as they gained more
169 confidence and experience through the sustained delivery of their clinic.

170 *Locus of Control*

171 Many clinic-providing participants portrayed a strong internal locus of control where they proactively
172 engaged with their multidisciplinary team (MDT), and drove the establishment of their outpatient roles
173 themselves; rather than relying upon their pharmacy department or management team. This strong
174 leadership often fostered creative solutions to barriers and facilitated external funding and resource for
175 their outpatient role.

176 In contrast, an external locus of control predominated in the non-clinic providers who described a need
177 to be directly presented with opportunities and resources from either pharmacy management or the
178 MDT; whilst some divulged previous unsuccessful requests for funding from pharmacy services.
179 Pertinent to this was a perceived requisite to obtain permission from pharmacy management before
180 pursuing potential outpatient roles within their MDTs. However, there were no formal examples of
181 permission being denied, and even departmental assurances about the non-requirement for permission
182 did not always provide participants with reassurance.

183 A difference in viewpoint between whose role it is to develop services, provide solutions, and find or
184 restructure resource seemed apparent between clinic- and non-clinic providing pharmacists.

185 **Clinic structure and processes**

186 *Defined patient cohorts in initial stages*

187 Clinic-providing pharmacists detailed how their role was created to provide a service to a clearly defined
188 cohort of patients, and that they had a clear understanding with their MDT about what patients they
189 would review. Once they became more comfortable with their role, they were provided with further
190 opportunities to take responsibility for an expanded cohort of patients. In some cases, this led to even
191 more resource to continue and expand their outpatient role within their MDT.

192 *Integration within standard patient treatment pathways*

193 All clinic providers could clearly define their MDT outpatient model and how patients were referred to
194 their pharmacist-led clinic. Clinic providers were typically able to detail how their clinic improved the
195 overall service efficiency or effectiveness. In contrast, non-clinic providers provided examples of being
196 uncertain where they fit within the outpatient journey.

197 *Exemplar peers*

198 The clinic providers highlighted the value of collaborating with a network of pharmacists who were
199 already providing a clinic, similar to their own. However, non-clinic providers revealed that without an
200 exemplar they struggled to establish a new clinic, or expand their existing role within their MDT.

201 *Practical and administrative Support*

202 All participants disclosed how their lack of knowledge about the processes for establishing a clinic
203 hindered their progress in implementing them. However, clinic providers described how administrative
204 support from within their MDT allowed them to better manage the administrative tasks and workload
205 associated with their outpatient clinic (e.g. dictation). The biggest physical barrier to clinic provision
206 was the need for clinic space, though the MDT provided this in most cases. The provision of support
207 from other MDT members was viewed as essential by all clinic-providing pharmacists to assist with the
208 progression of their clinic training and integration into the MDT outpatient model.

209 **Additional clinical skills and training**

210 *Prescribing, examination and consultation skills*

211 Most clinic-providing pharmacists acknowledged the benefits of obtaining and developing extra clinical
212 skills and training (e.g. physical examination). However, despite obtaining more additional clinical
213 skills and post-graduate qualifications (see Table 1), the non-clinic providers perceived a need for
214 further clinic-specific skills and training. Others highlighted that until they had obtained their
215 independent prescribing qualification, they were unable to provide the clinic, or were reliant on other
216 MDT members to carry out prescribing activities for their patients.

217 *Mentorship and preceptorship of clinical skills*

218 Clinic-providing pharmacists described the value of having a mentor to support their training. Some
219 recounted shadowing and observing their peers or MDT colleagues who were already running a similar
220 type of clinic, and explained that this allowed them to gain a better understanding of the clinic setting
221 and specialist practice. Others described the benefits of having a preceptor who assessed their individual
222 progress and level of competency, in addition to providing clinical support and reassurance during the
223 earlier stages of their training and clinic provision.

224 **Competing priorities**

225 *Additional resource required*

226 For most non-clinic providers, it was felt that more resource or some kind of “backfill” was essential to
227 allow them the opportunity to expand their inpatient role into the outpatient setting. Many felt that the
228 current staffing within their hospital pharmacy team was insufficient to cover their inpatient workload
229 and commitments; in general, or with reference to specific tasks (e.g. medicines reconciliation,
230 screening discharge prescriptions).

231 Clinic-providing pharmacists detailed how initially they either: had temporary (e.g. funding to provide
232 a clinic 2 days per week) or no extra resource, but managed to demonstrate cost-effectiveness and
233 service efficiency through their outpatient role, which resulted in the provision of extra resource from
234 the institution, and allowed them to further expand their role within the outpatient service.

235 *Prioritisation of Workload*

236 Most non-clinic providers revealed that the inpatient workload was their priority and that it was unclear
237 to them if clinic provision was a priority. Many could not see beyond their inpatient commitments to
238 afford time to explore opportunities within the outpatient setting. Some described a fear of the potential
239 consequences of sacrificing their inpatient workload and were concerned of the potential impact this
240 would have on their pharmacy colleagues or other HCPs based in the clinical areas they cover.

241 Some clinic-providing pharmacists explained that, despite having no extra resource, they managed the

242 inpatient workload and prioritised their outpatient role through informal arrangements with the rest of
243 their hospital pharmacy team (e.g. arranged cover for their workload during their protected clinic time).
244 Others described having flexible working-time arrangements between their MDTs and their pharmacy
245 department to facilitate the expansion of their role into the outpatient setting.

246 **Macro level pharmacy working**

247 Participants commonly realised the need for wide-scale working, beyond their own roles. The approach
248 to this typically differed, however, between clinic-providers and non-clinic-providers.

249 *Whole system working (cross-sector)*

250 Many participants highlighted that they felt there were differences in the opportunities available for
251 different pharmacists in different areas of practice; the most commonly cited example was the greater
252 prioritisation of service development in primary care over the secondary care setting. However, this
253 feeling of inequality was even felt between different pharmacy teams within the same hospital. Given
254 that the NHS is built on a premise of service equity and universality, some non-clinic providers were
255 concerned that the potential outpatient service they could provide in one hospital site would not
256 necessarily be replicable in another. Conversely, clinic-providers described coordinated working across
257 traditional boundaries with pharmacy colleagues from different sectors and locations; utilising shared
258 resources to facilitate expanded outpatient services.

259 *Team-level changes and beyond*

260 A desire for widespread change at the health authority level was pertinent amongst all pharmacists, and
261 changing current practice at individual hospital sites or teams was deemed insufficient to allow the
262 wider progression of the pharmacist role to the outpatient setting. Some participants, whether they
263 provided a clinic or not, expanded on this and highlighted the need for prioritising personal and service
264 development over inpatient workload, and that this needed to be made clearer at the health authority
265 level to facilitate this large-scale change.

266 One proposed solution from many clinic- and non-clinic providers was a greater role for their technician
267 colleagues to take on inpatient-associated tasks that were traditionally only carried out by pharmacists
268 (e.g. medicines reconciliation); two pharmacists explained how they have already integrated clinical
269 technicians within their teams to allow them to prioritise the expansion of their outpatient clinic role.

270 **External stakeholder relationships**

271 *MDT recognition of pharmacist outpatient role*

272 MDT awareness of the potential benefits that a pharmacist could bring to their teams was viewed as
273 essential; all participants explained that without pharmacy promotion, potential clinic-providing
274 opportunities would likely go to other HCPs. Many non-clinic providers desired senior pharmacist
275 support to facilitate these external relationships, and to promote the pharmacist role within the
276 outpatient setting at the executive level. However, despite not yet approaching MDT members
277 themselves, most revealed a belief that MDT members would support the idea of a pharmacist within
278 their outpatient service, and that this was not a barrier. Conversely, clinic-providing pharmacists
279 explained that after promoting their role for a period of time, their MDT is aware of their value to such
280 an extent that they present new potential opportunities directly to them.

281 *Patient recognition of pharmacist outpatient role*

282 Clinic and non-clinic providers discussed the potential benefits that positive patient recognition of the
283 pharmacist can have to enabling new opportunities for clinic provision. Some reported positive informal
284 patient feedback, whilst others revealed patient-reported gaps (e.g. there is currently no pharmacist input
285 to a service that treats a condition which mostly involves medicine prescribing, monitoring and
286 adjustment) in their current service provision by other HCPs, especially in relation to their medicines
287 management

288

289 A visual illustration of how all of these themes relate over time at different stages of clinic provision is
290 shown in Figure 1.

292 **DISCUSSION**

293 **Statement of key findings**

294 Participants in this study described multiple complex overlapping enablers and barriers to clinic
295 provision. These included: clinic prerequisites and requirements, as well as knowledge and support for
296 the practical and clinical aspects of clinic provision; individual factors and competing priorities;
297 pharmacy-team specific factors, from the micro to the macro level; competing priorities; the roles of
298 preceptors, mentors and peers; and relationships with external stakeholders, such as the MDT and
299 patients.

300 Clinic-providing pharmacists frequently revealed the benefits of obtaining several clinic pre-requisites
301 such as: a clear service need, support and resource from senior hospital department staff, a clearly
302 defined cohort of patients to manage, MDT integration and support, administrative support, and
303 protected clinic slots and physical spaces. Globally, these are all established enablers to clinic provision
304 by other HCPs [21, 42, 43], with some of these also potentially aiding the progression of clinical
305 pharmacy services and independent prescribing activities [22, 23, 44, 45].

306 Despite having achieved a greater number of additional clinical skills and post-graduate qualifications,
307 the desire for further skills and training amongst non-clinic providing pharmacists was prominent;
308 indicating that the training provided by current post-graduate courses may be inadequate to overcome
309 certain practical barriers. With participants in our study highlighting the benefits of mentorship and
310 preceptorship; more clinic-specific training and direct supervision which incorporates these, seems a
311 logical approach.

312 Individual factors predominated throughout the interviews, and are widely reported worldwide as
313 barriers to pharmacists progressing their roles, and undertaking clinical activities such as independent
314 prescribing and research [23, 45-49]. Our findings that MDT integration and support gradually
315 addressed the issues of confidence and clinical competency, are also supported by the literature [44-
316 46]. However, as well as at the individual level, participants revealed organisational level features. Non-

317 clinic providers disclosed a perceived need for permission from senior pharmacists and pharmacy
318 services. This is substantiated by existing literature that details a lack of progression in clinical activities
319 carried out by pharmacists without management approval and support [23, 45, 46, 50]. However, in our
320 study there were no formal cases of participants being denied permission; this fatalism has previously
321 been highlighted as a barrier to NHS pharmacists undertaking research [50].

322 The need to overcome barriers with creative solutions that result in the implementation of their
323 outpatient role was evident in our study. This requisite for creative leadership to facilitate clinic
324 provision is not unique to pharmacists [21]. Participants revealed competing individual priorities and
325 perceived differences between different pharmacy teams in hospital- and community-based settings;
326 these issues appear to also hinder the development of hospital-based pharmacy services in other
327 countries [23].

328 Although our inductive analysis was not framed *a-priori* around implementation science, our findings
329 fit well into the five domains described in the Consolidated Framework For Implementation Research
330 [51]; intervention characteristics (e.g. independent prescribing and additional clinical skills), outer
331 setting (e.g. multidisciplinary integration and relationships), inner setting (e.g. department vision,
332 competing priorities, protected time for clinics), individuals (e.g. confidence, locus of control), and the
333 process of implementation (e.g. preceptorship, practical and administrative elements of setting a clinic
334 up). Utilising such frameworks may offer means to realise changes at the macro-level.

335 **Strengths & Weaknesses**

336 This study not only produced qualitative data about the barriers, but also detailed enablers from the
337 actual insights and experiences of participants that succeeded in a system where these barriers are
338 present to now provide clinics routinely as part of their role.

339 This evaluation covered the largest health authority in Scotland, and our purposive sampling strategy
340 enabled us to obtain qualitative data from clinic- and non-clinic providing hospital pharmacists, with a
341 variety of different demographic and professional characteristics [26, 27].

342 There were some limitations. The interviewer (GB) was known in a professional capacity by some
343 participants which may have introduced some response bias. However, the potential benefits of
344 interviewer-respondent familiarity and rapport have been reported, but the effects of this on the quality
345 of data are still not fully understood [52-57]. This study was carried out within one regional health
346 authority and it is unclear if all of these findings would be applicable to other health authorities.

347

348 **Interpretation & Further Research**

349 Our study suggests that individual- or hospital-level changes alone will be insufficient to progress
350 wholesale change. The results raise a broader question; whose job is it to develop new roles and new
351 services, clinicians or organisations/managers? Our study hints that there is not a consensus view in the
352 incumbent workforce and that many individual barriers may be secondary to a systematic discord in the
353 current workforce model as to whose responsibility it is to develop new roles and to take forward new
354 service developments (e.g. where should the locus of control sit?).

355 Scotland is beginning to address this issue through the publication of national pharmacist career
356 pathway review, and the operationalisation of new Royal Pharmaceutical Society professional curricula
357 [58, 59]. These changes will link all pharmacists to an appropriate national curricula, which intends to
358 support the development of clinical skills, including autonomously managing clinical risk, and non-
359 clinical skills, inclusion leadership, service development, education of less experienced colleagues and
360 research/service evaluation [58, 59]. Such curricula are intended to evidence skills application, rather
361 than the acquirement of new knowledge. To increase the likelihood of success with these bold visions,
362 completion of such curricula needs to be linked to career reward and progression [60]. Further research
363 would need to test how to implement, and to what extent pharmacists accept, responsibilities of formal
364 distributed leadership [60]. Broader work is also required within NHS Scotland to define and implement
365 appropriate support-structures [61]. Prospective research should assess the impact of this vision on
366 professional confidence and efficacy, and ultimately outpatient clinic provision.

367 **CONCLUSION**

368 The complex enablers and barriers to hospital pharmacists providing outpatient clinics are multifaceted
369 and will unlikely be resolved by one single intervention. Changes are required at the micro-level (e.g.
370 individual and team) and the macro-level (e.g. institution and health authority). A broader over-arching
371 question of ‘whose job is it to develop new roles and new services’ remains unclear. The forthcoming
372 implementation of new professional curricula may enable pharmacists to overcome the individual and
373 systematic barriers that prevent them from currently progressing the development of outpatient clinic
374 services; prospective research needs to accompany this vision.

375

376 **Acknowledgements:** The authors would like to thank all the pharmacists who participated in this
377 study.

378

379 **Funding:** This research received no specific grant from any funding agency in the public, commercial,
380 or not-for-profit sectors.

381

382 **Conflicts of interest:** None.

383

384 **REFERENCES**

385 1. Pande S, Hiller JE, Nkansah N, *et al.* The effect of pharmacist-provided non-dispensing services on patient
386 outcomes, health service utilisation and costs in low- and middle-income countries. *Cochrane Database Syst*
387 *Rev.* 2013 Feb 28; (2): CD010398. doi: 10.1002/14651858.CD010398. PMID: 23450614.

388 2. Nkansah N, Mostovetsky O, Yu C, *et al.* Effect of outpatient pharmacists' non-dispensing roles on patient
389 outcomes and prescribing patterns. *Cochrane Database Syst Rev.* 2010 Jul 7; (7): CD000336. doi:
390 10.1002/14651858.CD000336.pub2. PMID: 20614422; PMCID: PMC7087444.

391 3. Ryan R, Santesso N, Lowe D, *et al.* Interventions to improve safe and effective medicines use by
392 consumers: an overview of systematic reviews. *Cochrane Database Syst Rev.* 2014 Apr 29; (4): CD007768.
393 doi: 10.1002/14651858.CD007768.pub3. PMID: 24777444; PMCID: PMC6491214.

394 4. Weeks G, George J, Maclure K, *et al.* Non-medical prescribing versus medical prescribing for acute and
395 chronic disease management in primary and secondary care. *Cochrane Database Syst Rev.* 2016 Nov 22; 11
396 (11): CD011227. doi: 10.1002/14651858.CD011227.pub2. PMID: 27873322; PMCID: PMC6464275.

397 5. Poh EW, McArthur A, Stephenson M, *et al.* Effects of pharmacist prescribing on patient outcomes in the
398 hospital setting: a systematic review. *JBI Database System Rev Implement Rep.* 2018 Sep; 16 (9): 1823-
399 1873. doi: 10.11124/JBISRIR-2017-003697. PMID: 30204671.

400 6. Department of Health. Improving Patients' Access to Medicines: A Guide to Implementing Nurse and
401 Pharmacist Independent Prescribing within the NHS in England [internet]. London (UK): Department of
402 Health; 2006 Apr. Available from:
403 https://webarchive.nationalarchives.gov.uk/20130105033522/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4133747.pdf (Accessed: 14 Nov 2020).

405 7. General Pharmaceutical Council. Standards for the education and training of pharmacist independent
406 prescribers [internet]. London (UK): General Pharmaceutical Council; 2019 Jan. Available from:
407 [https://www.pharmacyregulation.org/sites/default/files/document/standards-for-the-education-and-training-](https://www.pharmacyregulation.org/sites/default/files/document/standards-for-the-education-and-training-of-pharmacist-independent-prescribers-january-19.pdf)
408 [of-pharmacist-independent-prescribers-january-19.pdf](https://www.pharmacyregulation.org/sites/default/files/document/standards-for-the-education-and-training-of-pharmacist-independent-prescribers-january-19.pdf) (Accessed: 14 Nov 2020).

409 8. O'Brien N, Hoskins C. Pilot of a Pharmacist Independent Prescriber in Orthopaedic Admissions suite
410 (OAS) to support the Enhanced Recovery After Surgery (ERAS) project for patients undergoing Hip and
411 Knee replacement Surgery and to reduce length of stay. UKCPA Joint Poster presentation at the National
412 Conference; 2014 April 4-6; Manchester (UK). Available from: [http://ukclinicalpharmacy.org/wp-](http://ukclinicalpharmacy.org/wp-content/uploads/2017/05/UKCPA-GHP_Conference_Abstracts_April2014.pdf)
413 [content/uploads/2017/05/UKCPA-GHP_Conference_Abstracts_April2014.pdf](http://ukclinicalpharmacy.org/wp-content/uploads/2017/05/UKCPA-GHP_Conference_Abstracts_April2014.pdf) (Accessed: 14 Nov 2020).

- 414 9. Baqir W, Crehan O, Murray R, *et al.* Pharmacist prescribing within a UK NHS hospital trust: nature and
415 extent of prescribing, and prevalence of errors. *Eur J Hosp Pharm.* 2014; 22: 79–82. doi: 10.1136/ejpharm-
416 2014-000486.
- 417 10. Rush C, Forsyth P, Moir L, *et al.* Collaborative care with a pharmacist improves optimisation of secondary
418 prevention medication after discharge in patients with left ventricular systolic dysfunction due to acute
419 myocardial infarction. *Eur J Heart Fail.* 2015; 17: S1 (pp 341). doi: 10.1002/ejhf.277.
- 420 11. Vaghela T, Ramesh C. Impact of change in practice: pharmacist-led respiratory syncytial virus (RSV)
421 immunoprophylaxis clinic. *Arch Dis Child.* 2011; 96 (4): e1. doi: 10.1136/adc.2011.211243.7.
- 422 12. Scottish Government. Public Health Priorities for Scotland [internet]. Edinburgh (Scotland): The Scottish
423 Government; 2018 Jun. Available from: [https://www.gov.scot/publications/scotlands-public-health-](https://www.gov.scot/publications/scotlands-public-health-priorities/)
424 [priorities/](https://www.gov.scot/publications/scotlands-public-health-priorities/) (Accessed: 14 Nov 2020).
- 425 13. Scottish Government. The Scottish Health Survey 2019 – volume 1: main report [internet]. Edinburgh
426 (Scotland): The Scottish Government; 2020 Sep. Available from:
427 <https://www.gov.scot/publications/scottish-health-survey-2019-volume-1-main-report/> (Accessed: 14 Nov
428 2020).
- 429 14. Information Services Division: Public Health Scotland. Acute hospital activity and NHS Beds Information
430 for Scotland (Annual – Year ending 31 March 2019) [internet]. Edinburgh (Scotland): Public Health
431 Scotland; 2019 Sep. Available from:
432 [https://beta.isdscotland.org/find-publications-and-data/health-services/hospital-care/acute-hospital-activity-](https://beta.isdscotland.org/find-publications-and-data/health-services/hospital-care/acute-hospital-activity-and-nhs-beds-information-annual/10-september-2019/)
433 [and-nhs-beds-information-annual/10-september-2019/](https://beta.isdscotland.org/find-publications-and-data/health-services/hospital-care/acute-hospital-activity-and-nhs-beds-information-annual/10-september-2019/) (Accessed: 29 Nov 2020).
- 434 15. Scottish Government. A National Clinical Strategy For Scotland [internet]. Edinburgh (Scotland): The
435 Scottish Government; 2016 Feb. Available from: [https://www.gov.scot/publications/national-clinical-](https://www.gov.scot/publications/national-clinical-strategy-scotland/)
436 [strategy-scotland/](https://www.gov.scot/publications/national-clinical-strategy-scotland/) (Accessed: 14 Nov 2020).
- 437 16. Royal College of Physicians. Outpatients: The future - adding value through sustainability [internet].
438 London (UK): Royal College of Physicians; 2018. Available from:
439 <https://www.rcplondon.ac.uk/projects/outputs/outpatients-future-adding-value-through-sustainability>
440 (Accessed: 14 Nov 2020).
- 441 17. Scottish Government. The Modern Outpatient: A Collaborative Approach 2017-2020 [internet]. Edinburgh
442 (Scotland): The Scottish Government; 2016 Dec. Available from:

- 443 <https://www.gov.scot/publications/modern-outpatient-collaborative-approach-2017-2020/> (Accessed: 14
444 Nov 2020).
- 445 18. Scottish Government. Achieving Excellence in Pharmaceutical Care: A Strategy for Scotland [internet].
446 Edinburgh (Scotland): The Scottish Government; 2017 Aug. Available from:
447 <http://www.gov.scot/Publications/2017/08/4589> (Accessed: 14 Nov 2020).
- 448 19. Scottish Government. A Plan For Scotland: 2016-17 [internet]. Edinburgh (Scotland): The Scottish
449 Government; 2016 Sep. Available from: <https://www2.gov.scot/Resource/0050/00505210.pdf> (Accessed:
450 14 Nov 2020).
- 451 20. Forsyth P, Moir L, Speirits I, *et al.* Improving medication optimisation in left ventricular systolic
452 dysfunction after acute myocardial infarction. *BMJ Open Qual.* 2019; 8 (3): e000676. doi: 10.1136/bmjopen-
453 2019-000676. PMID: 31544164; PMCID: PMC6730630.
- 454 21. Haines KJ, McPeake J, Hibbert E, *et al.* Enablers and Barriers to Implementing ICU Follow-Up Clinics and
455 Peer Support Groups Following Critical Illness: The Thrive Collaboratives. *Crit Care Med.* 2019 Sep; 47
456 (9): 1194-1200. doi: 10.1097/CCM.0000000000003818. PMID: 31241499; PMCID: PMC6699486.
- 457 22. Salgado TM, Moles R, Benrimoj SI, *et al.* Exploring the role of renal pharmacists in outpatient dialysis
458 centres: a qualitative study. *Int J Clin Pharm.* 2012 Aug; 34 (4): 569-578. doi: 10.1007/s11096-012-9645-z.
- 459 23. Brazinha I, Fernandez-Llimos F. Barriers to the implementation of advanced clinical pharmacy services at
460 Portuguese hospitals. *Int J Clin Pharm.* 2014 Oct; 36 (5): 1031-1038. doi: 10.1007/s11096-014-9991-0.
- 461 24. NHS Greater Glasgow and Clyde [internet]. Our hospitals: Our Hospitals and Sites. Available from:
462 <https://www.nhsggc.scot/hospitals-services/our-hospitals/> (Accessed: 17 May 2022).
- 463 25. Scottish Government. Scottish Index of Multiple Deprivation 2020: introduction [internet]. Edinburgh
464 (Scotland): Scottish Government; 2020 Jan. Available from: [https://www.gov.scot/publications/scottish-
465 index-multiple-deprivation-2020/](https://www.gov.scot/publications/scottish-index-multiple-deprivation-2020/) (Accessed: 08 Dec 2020).
- 466 26. Etikan I, Musa SA, Alkassim RS. Comparison of convenience sampling and purposive sampling. *Am J*
467 *Theor Appl Stat.* 2016; 5: 1-4. doi: 10.11648/j.ajtas.20160501.11
- 468 27. Ritchie J, Lewis J, Elam G, Tennant R, Rahim N. Chapter 5: Designing and Selecting Samples. In: Ritchie
469 J, Lewis J, McNaughton Nicolls C, Ormston R, editors. *Qualitative Research Practice: A Guide for Social*
470 *Science Students and Researchers*, 2nd edition. London (UK): SAGE Publications; 2013. p 111-119.
- 471 28. Adler PA, Adler P. Limitations to sample pools. In: Baker SE, Edwards R, Doidge M, editors. *National*
472 *centre of research review paper: how many qualitative interviews is enough?: expert voice and early career*

- 473 reflections on sampling and cases in qualitative research. Southampton (UK): National Centre for Research
474 Methods; 2012. p 10.
- 475 29. Guest G, Bunce A, Johnson L. How Many Interviews Are Enough?: An Experiment with Data Saturation
476 and Variability. *Field Methods*. 2006; 18 (1), 59–82. doi: 10.1177/1525822X05279903.
- 477 30. Namey E, Guest G, McKenna K, *et al*. Evaluating Bang for the Buck: A Cost-Effectiveness Comparison
478 Between Individual Interviews and Focus Groups Based on Thematic Saturation Levels. *Am J Eval*. 2016;
479 37 (3), 425–440. doi: 10.1177/1098214016630406.
- 480 31. Microsoft [Internet]. Microsoft 365: Microsoft Teams. Available from: [https://www.microsoft.com/en-](https://www.microsoft.com/en-gb/microsoft-365/microsoft-teams/group-chat-software)
481 [gb/microsoft-365/microsoft-teams/group-chat-software](https://www.microsoft.com/en-gb/microsoft-365/microsoft-teams/group-chat-software) (Accessed: 08 Dec 2020).
- 482 32. QSR International [Internet]. NVivo: Qualitative Data Analysis. Available from:
483 <https://www.qsrinternational.com/nvivo-qualitative-data-analysis-software/about/nvivo> (Accessed: 08 Dec
484 2020).
- 485 33. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol*. 2006; 3: 77-101. doi:
486 10.1191/1478088706qp063oa.
- 487 34. Nowell LS, Norris JM, White DE, *et al* J. Thematic Analysis: Striving to Meet the Trustworthiness Criteria.
488 *Int J Qual Methods*. 2017; 16: 1-13. doi: 10.1177/1609406917733847.
- 489 35. DeSantis L, Ugarriza DN. The concept of theme as used in qualitative nursing research. *West J Nurs Res*.
490 2000 Apr; 22 (3): 351-372. doi: 10.1177/019394590002200308. PMID: 10804897.
- 491 36. Joffe H. Chapter 15: Thematic Analysis. In: Harper D, Thompson A, editors. *Qualitative Research Methods*
492 *in Mental Health and Psychotherapy: A Guide for Students and Practitioners*. Chichester (UK): Wiley-
493 Blackwell; 2012. p 209-224.
- 494 37. Webster S, Lewis J, Brown A. Chapter 4: Ethical Considerations in Qualitative Research. In: Ritchie J,
495 Lewis J, McNaughton Nicolls C, Ormston R, editors. *Qualitative Research Practice: A Guide for Social*
496 *Science Students and Researchers*, 2nd edition. London (UK): SAGE Publications; 2013. p 77-110.
- 497 38. Côté L, Turgeon J. Appraising qualitative research articles in medicine and medical education. *Med Teach*.
498 2005; 27 (1): 71-75. doi: 10.1080/01421590400016308. PMID: 16147774.
- 499 39. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item
500 checklist for interviews and focus groups. *Int J Qual Health Care*. 2007; 19 (6): 349–357. doi:
501 10.1093/intqhc/mzm042.

- 502 40. Scottish Terms and Conditions Committee (STAC). Proposal for Reform of Agenda for Change in NHS
503 Scotland (Framework Agreement) [internet]. 2018 Aug. Available from: [https://www.stac.scot.nhs.uk/wp-](https://www.stac.scot.nhs.uk/wp-content/uploads/Test.pdf)
504 [content/uploads/Test.pdf](https://www.stac.scot.nhs.uk/wp-content/uploads/Test.pdf) (Accessed on 6 Dec 2020).
- 505 41. General Medical Council [internet]. GMC approved postgraduate curricula. Available from:
506 <https://www.gmc-uk.org/education/standards-guidance-and-curricula/curricula> (Accessed: 29 Nov 2020).
- 507 42. Hatchett R. Nurse-led clinics: 10 essential steps to setting up a service. *Nursing Times*. 2008; 104 (4): 62-
508 64.
- 509 43. Berei T, Forsyth P, Balakumaran K, *et al*. Implementing Nonphysician Provider Guideline-Directed
510 Medical Therapy Heart Failure Clinics: A Multi-National Imperative. *J Card Fail*. 2021; 27 (8): 896-906.
511 doi: 10.1016/j.cardfail.2021.06.001. PMID: 34364666.
- 512 44. Fisher J, Kinnear M, Reid F, *et al*. What supports hospital pharmacist prescribing in Scotland? – A mixed
513 methods, exploratory sequential study. *Res Social Adm Pharm*. 2018; 14: 488-497. doi:
514 10.1016/j.sapharm.2017.06.007.
- 515 45. Graham-Clarke E, Rushton A, Noblet T, *et al*. Facilitators and barriers to non-medical prescribing - A
516 systematic review and thematic synthesis. *PLoS One*. 2018 Apr; 13 (4): e0196471. doi:
517 10.1371/journal.pone.0196471. PMID: 29709006; PMCID: PMC5927440.
- 518 46. General Pharmaceutical Council. Prescribers Survey Report [internet]. London (UK): General
519 Pharmaceutical Council; 2016 May. Available from:
520 [https://www.pharmacyregulation.org/sites/default/files/document/gphc_prescribers_survey_report-may-](https://www.pharmacyregulation.org/sites/default/files/document/gphc_prescribers_survey_report-may-2016.pdf)
521 [2016.pdf](https://www.pharmacyregulation.org/sites/default/files/document/gphc_prescribers_survey_report-may-2016.pdf) (Accessed: 14 Nov 2020).
- 522 47. Frankel GE, Austin Z. Responsibility and confidence: Identifying barriers to advanced pharmacy practice.
523 *Can Pharm J (Ott)*. 2013 May; 146 (3): 155-161. doi: 10.1177/1715163513487309.
- 524 48. Rosenthal M, Austin Z, Tsuyuki RT. Barriers to pharmacy practice change: Is it our nature or nurture? *Can*
525 *Pharm J (Ott)*. 2016 Nov; 149 (6): 317-319. doi: 10.1177/1715163516672832.
- 526 49. Rosenthal M, Austin Z, Tsuyuki RT. Are Pharmacists the Ultimate Barrier to Pharmacy Practice
527 Change? *Canadian Pharmacists Journal / Revue des Pharmaciens du Canada*. 2010; 143 (1): 37-42.
528 doi:10.3821/1913-701X-143.1.37.
- 529 50. Lowrie R, Morrison G, Lees R, *et al*. Research is 'a step into the unknown': an exploration of pharmacists'
530 perceptions of factors impacting on research participation in the NHS. *BMJ Open*. 2015 Dec 30; 5 (12):
531 e009180. doi: 10.1136/bmjopen-2015-009180.

- 532 51. Damschroder LJ., Aron DC., Keith RE. *et al.* Fostering implementation of health services research findings
533 into practice: a consolidated framework for advancing implementation science. *Implementation Sci.* 2009; 4
534 (50). doi: 10.1186/1748-5908-4-50.
- 535 52. Mitchell K, Wellings K, Elam G, *et al.* How can we facilitate reliable reporting in surveys of sexual
536 behaviour? Evidence from qualitative research. *Culture, Health and Sexuality.* 2007; 9 (5): 519-531. doi:
537 10.1080/13691050701432561.
- 538 53. Tu SH, Liao PS. Social Distance, Respondent Cooperation and Item Nonresponse in Sex Survey. *Quality*
539 *and Quantity.* 2007; 41: 177-199. doi: 10.1007/s11135-007-9088-0.
- 540 54. Rodriguez LA, Sana M, Sisk B. Self-administered Questions and Interviewer-Respondent Familiarity. *Field*
541 *Methods.* 2015; 27 (2): 163-181. doi: 10.1177/1525822X14549315.
- 542 55. Rossier C. Estimating induced abortion rates: A review. *Stud Fam Plann.* 2003; 34 (2): 87-102.
543 doi: 10.1111/j.1728-4465.2003.00087.x.
- 544 56. Weinreb AA, Sana M, Stecklov G. A test of the stranger-interviewer norm in the Dominican Republic.
545 *Popul Stud (Camb).* 2016; 70 (1): 73-92. doi: 10.1080/00324728.2016.1139740.
- 546 57. Stecklov G, Weinreb AA, Sana M. Family Planning for Strangers: An Experiment on the Validity of
547 Reported Contraceptive Use. *PLoS One.* 2015; 10 (8): e0136972. doi: 10.1371/journal.pone.0136972.
548 PMID: 26322898; PMCID: PMC4554992.
- 549 58. NHS Education for Scotland. Pharmacist Career Framework Review – Report of the Review Advisory
550 Group [internet]. Edinburgh (Scotland): NHS Education for Scotland; 2020 Sep. Available from:
551 https://www.nes.scot.nhs.uk/media/vzahxc4w/final-pharmacy-pg-framework-review_v1-1.pdf (Accessed
552 14 Jan 2021).
- 553 59. Royal Pharmaceutical Society. The RPS Advanced Pharmacy Framework (APF) [internet]. London (UK):
554 Royal Pharmaceutical Society; 2013. Available from:
555 [https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/Frameworks/RPS%20A
556 dvanced%20Pharmacy%20Framework.pdf](https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/Frameworks/RPS%20Advanced%20Pharmacy%20Framework.pdf) (Accessed 14 Jan 2021).
- 557 60. Martin G, Beech N, MacIntosh R, *et al.* Potential challenges facing distributed leadership in health care:
558 evidence from the UK National Health Service. *Sociol Health Illn.* 2015 Jan; 37(1): 14-29. doi:
559 10.1111/1467-9566.12171. Epub 2014 Dec 20. PMID: 25529349.

560 61. Forsyth P, Rushworth GF. Advanced pharmacist practice: where is the United Kingdom in pursuit of this
561 'Brave New World'?. *Int J Clin Pharm*. 2021 May 15. <https://doi.org/10.1007/s11096-021-01276-5>. Epub
562 ahead of print. PMID: 33991288.
563

Table 1. Characteristics of participating pharmacists

Variables	Pharmacists who provided a clinic (n = 8)	Pharmacists who did not provide a clinic (n = 8)	Both cohorts combined (n = 16)
Participants	P1, P2, P4, P5, P6, P8, P10, P13	P3, P7, P9, P11, P12, P14, P15, P16	
Age, years Median (IQR)	38.5 (31.0 – 42.5)	35.0 (29.5 – 39.5)	38.0 (30.5 – 40.0)
Gender, n			
Female	5	6	11
Male	3	2	5
Time qualified as a pharmacist, years Median (IQR)	16.0 (8.0 – 20.5)	12.0 (6.5 – 16.5)	15.5 (7.5 – 18.0)
Time practising as a hospital pharmacist, years Median (IQR)	13.0 (8.0 – 19.5)	12.0 (6.5 – 16.0)	12.5 (7.5 – 16.5)
Achieved an Independent Prescribing qualification, n	8	7	15
Time qualified as an Independent Prescriber, years Median (IQR)	3.8 (2.0 – 8.3)	2.1 (0.3 – 3.0)	3.0 (0.8 – 4.5)
NHS Pay Grade/ Banding ^a , n			
Band 6	0	1	1
Band 7	2	3	5
Band 8a	5	3	8
Band 8b	1	1	2
Working time per week ^b , hours Median (IQR)	37.5 (32.8 – 37.5)	35.75 (30.0 – 37.5)	37.5 (30.0 – 37.5)
Frequency of rotation through more than one specialty in their current role ^c , n			
Doesn't occur in current role	7	4	11
Daily	0	3	3
Weekly	1	0	1
Monthly	0	1	1
Additional post-graduate qualifications, n			
Post-graduate diploma	4	5	9
Masters degree	4	5	9
Additional clinical skills/training ^d , n			
Clinical skills	5	6	11
Consultation skills	2	3	5
Advanced clinical assessment	1	0	1
Venepuncture	1	0	1

IQR = Interquartile Range (Q1 – Q3); NHS = National Health Service.

^aNHS Pay Grade / Banding as specified by the NHS Scotland – Scottish Terms & Conditions Committee [40].

^bStandard full time working hours in NHS Scotland are 37.5 hours per week.

^cSpecialties as defined by the General Medical Council [41].

^dAdditional skills/training were viewed by participants as being achieved following the completion of a nationally recognised course.

Table 2. Illustrative quotes from interviews highlighting themes and sub-themes


Theme	Sub-Theme	Exemplar Enabler Quote	Exemplar Barrier Quote
Clinical or service need	N/A	'... [the clinic] really worked and happened quickly for me because the directorate* needed it to happen.' (P5)	No examples given by participants
Individual factors	Personal motivation	'I think it [providing a clinic] would give people a huge sense of job satisfaction as well... it is something I am definitely keen to do in the near future.' (P11)	No examples given by participants
	Confidence with Risk	'I had a lot of experience of working with inpatient cardiology; so, I had a pretty good understanding of the background for medicines and treatment rationale...it's like anything, once you do it [the clinic] long enough that level of anxiety or trepidation decreases as you become more confident and familiar with the processes.' (P10)	Lack of confidence in clinical decision making: '...but you won't have that security because you'll have to make the decisions all by yourself.' (P12) Fear of the potential clinical risks: 'I am still actually quite terrified of being alone with a patient, within a room.' (P4)
	Locus of Control	Internal Locus of Control: 'I feel you really have to push the doors open yourself because things aren't going to come for you. You've got to show the value of a pharmacy service because nobody is going to come up to you and say, "Here's a big pool of money, can you set up a clinic?'" (P5) Leadership leading to creative solutions: '...we had put a model together for a clinic and with the MCN, everybody had agreed that there was a need for pharmacist input and we went out and got our own money for it...we put in a grant application [to a drug company] and there was money given for technicians, as well as pharmacist's time.' (P14)	External Locus of Control: 'How can that be done without getting permission...?' (P15) Department providing assurances on permission does not always result in reassurance: 'We've had quite a clear message from the leads in pharmacy that we don't need permission to do something but I think that this is not true.' (P13) Needs solutions & resource provided directly: 'So we did approach our senior pharmacy team and asked if we could do this and we were told that we didn't have the money to pay for it.' (P16)
Clinic structure and processes	Defined Patient Cohorts in Initial Stages	'When I first started, I only saw rheumatoid arthritis patients but I now see all different types of patients.' (P6)	No examples given by participants
	Integration within standard patient treatment pathways	'she [consultant] really had a vision for where the pharmacist would fit into her clinic, and it was quite a pre-defined role that was easier to train towards because she knew what the goal was for the pharmacist...' (P2)	'How do we know where the gaps are in the outpatient service, and where does the pharmacist fit?' (P7)
	Exemplar Peers	Exemplar Peer Present: '...he [external pharmacist peer] was trying to establish the service, along with one of the consultants. So, I was lucky in a sense that there was an established service within the [hospital] which I could tap into.' (P10)	Exemplar Peer Absent: '...but it's just not something so far that has historical precedence. So, that in itself is a barrier. Just that these things don't exist yet.' (P3)
	Practical and administrative Support	Increasing knowledge of, and gaining administrative support for, the practical elements: 'It was mostly just the technical side of things I needed help with like, "Will I get a space? How do patients get appointed to my clinic? Will someone be able to do my dictations?" ... I spoke to the administration manager and she arranged for an assigned audio typist who now does all my dictations...just someone showing you how to work a Dictaphone and how to approve your clinic letters is important.' (P5)	Lack of knowledge of the clinic processes hindering its establishment: 'I guess, I was maybe a bit too enthusiastic and naive in the beginning by thinking, "this is such a fantastic opportunity, and I can't wait to get stuck in" ... but I don't think you could start a clinic without considering all these [practical] aspects...' (P16). Need for administrative support: '...I know it is very time consuming to do dictations or to do your own letters. So, we need to ensure we do have admin support for that, and I think that these are things that even the doctors struggle with at the moment within our service.' (P16)
Additional clinical skills & training	Prescribing, examination, and consultation skills	'...during my prescribing course, I've picked up all the skills for clinical assessment and consultation through those [NHS Education for Scotland] study days and then I went on to do an advanced clinical skills assessment course after I qualified... over time, definitely with practice and experience, picking up more, seeing more patients, that has all helped me to provide the service more confidently.' (P8)	Need for independent prescribing: 'I wasn't a prescriber when I first started doing this clinic...and it meant I was having to get medics or other pharmacists to write all my prescriptions for me after seeing patients in clinic.' (P1) Need for learning & updating clinical skills: 'So that [examining patients] would be completely new to me, and doing face to face consultations. So, I would need to go on courses for that, and even expand on my IP.' (P7)
	Mentorship and preceptorship of clinical skills	'...at the start; I was doing the clinic with the regular pharmacist being on at the same time in another room. I now feel more comfortable having to do that in that setting now.' (P8)	No examples given by participants

* = this refers to the local service

Table 2. Illustrative quotes from interviews highlighting themes and sub-themes (continued)

Competing priorities	Additional resource required	Using temporary resource to demonstrate cost-effectiveness leading to extra resource to expand outpatient role further: 'When I first started, I was only two days a week, and then we did quite a lot of work around the tapering and the cost-savings and at that point I was offered a third day [external MDT funding] because finance said from the savings made, they could offer me a third day'. (P6)	'...there would need to be some sort of backfill; that's the basic problem because we're a small team who cover a large unit; the same as everywhere I'm sure.' (P13) 'I think sometimes we barely even fulfil our inpatient commitments let alone to get out into resource centres to start setting up clinics.' (P9) 'I think it's probably due to the challenges of staffing and because of the staffing this means that people worry about the inpatient service before they even think about new service developments.' (P11)
	Prioritisation of Workload	Making informal arrangements with the pharmacy team prioritise outpatient role development: '...when you had your clinic day you just kind of had to build in cover, from your team. So, depending on where I was, someone would be able to cover where I was or what I was meant to be doing that afternoon, and vice versa.' (P4)	'I suppose fundamentally the most critical thing is ward-based duties such as: urgent clinical queries and discharge prescriptions because that has to happen for the maintenance of basic hospital.' (P3) Fear of the consequences if the inpatient workload is perceived to have been sacrificed: 'Because if I'm pulled from a clinic to do my other roles there's nobody to fill that and that would impact my colleagues, it'll impact patient care like for example, confirming meds and all that kind of thing'. (P13)
Macro level pharmacy working	Whole System Working (Cross-sector)	Whole-System working present: "there was, eh, agreement that there would be some appointments across [the health authority] which would have a split component of primary care and acute..." (P10)	Whole-System working absent: '...I am just maybe a bit bitter that the primary care pharmacists are getting to do [clinics] because that is something I wanted to do at one point'. (P9)
	Team-level changes and beyond	Changed other aspects of the team to facilitate outpatient role: '...we've moved a lot of the work on to the technicians' role, where we can, to be able to free up pharmacist time. So, I think we're more efficient now than we used to be with the pharmacist time.' (P1)	Believes Change Needs to be Beyond Their Level of Scope: 'I think there needs to be a significant overhaul ... in the way that we operate because there is limited sustainability and wiggle-room for conducting outpatient clinics. ... it's bigger than just being able to reshuffle individual pharmacy departments in order to have pharmacists introduce 1 or 2 new clinics ...' (P3)
External stakeholder relationships	MDT recognition of pharmacist outpatient role	Positive MDT relationships resulting in more opportunities to progress outpatient role: '...they [MDT] were trying to find a way that I could help their service even more and they needed times freed up for them to take on more acute clinics and patient assessment clinics, and it made sense for a pharmacist to do the therapeutic drug monitoring.' (P6)	Under-developed MDT Relationships Blocking Progress: 'I think there's a lack of a recognition or appreciation for what a pharmacist's role is, particularly within acute care. I think a lot of people see us as some sort of 'prescription provider' rather than an advisory or patient management service....' (P15)
	Patient recognition of pharmacist outpatient role	Positive patient feedback after experiencing a pharmacist-led clinic: 'Yeah, the patients love it. They think it's great. They love having someone who will talk to them about what's going to happen with their medicines.' (P13)	No examples given by participants

IP = independent prescribing; MCN = managed clinical network (NB- this is a local multi-professional service development committee); MDT = multidisciplinary team



IP = Independent Prescribing

Figure 1: Enablers (green) and barriers (pink) to the provision of outpatient clinics by hospital pharmacists



[Click here to access/download](#)

Electronic Supplementary Material
Supplementary File (1) - Interview Schedule 1.docx





[Click here to access/download](#)

Electronic Supplementary Material
Supplementary File (2) - Interview Schedule 2.docx

